
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE530C1F8AEE6D63050C1F007EF972FF.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="cureus">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Cureus">
<meta name="citation_title" content="Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management">
<meta name="citation_author" content="Abdul Hamid Zargar">
<meta name="citation_author_institution" content="Department of Endocrinology, Centre for Diabetes and Endocrine Care, Srinagar, IND">
<meta name="citation_author" content="Jayagopal Pathiyil Balagopalan">
<meta name="citation_author_institution" content="Department of Cardiology, Lakshmi Hospital, Palakkad, IND">
<meta name="citation_author" content="Arpandev Bhattacharyya">
<meta name="citation_author_institution" content="Department of Diabetes and Endocrinology, Manipal Hospital, Bengaluru, IND">
<meta name="citation_author" content="Alan Almeida">
<meta name="citation_author_institution" content="Department of Nephrology, Parmanand Deepchand (PD) Hinduja Hospital and Medical Research Center, Mumbai, IND">
<meta name="citation_author" content="Abhijit Taraphder">
<meta name="citation_author_institution" content="Department of Nephrology, Apollo Gleneagles Hospital, Kolkata, IND">
<meta name="citation_author" content="Sandeep Bansal">
<meta name="citation_author_institution" content="Department of Cardiology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, IND">
<meta name="citation_author" content="Sameer Dani">
<meta name="citation_author_institution" content="Department of Cardiology Services, Apollo Cardiovascular and Thoracic Institute, Ahmedabad, IND">
<meta name="citation_author" content="Nilakshi Deka">
<meta name="citation_author_institution" content="Department of Endocrinology, Apollo Hospital, Guwahati, IND">
<meta name="citation_author" content="Sanjay Jain">
<meta name="citation_author_institution" content="Department of Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND">
<meta name="citation_author" content="Onkar C Swami">
<meta name="citation_author_institution" content="Department of Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND">
<meta name="citation_publication_date" content="2025 Jul 22">
<meta name="citation_volume" content="17">
<meta name="citation_issue" content="7">
<meta name="citation_firstpage" content="e88561">
<meta name="citation_doi" content="10.7759/cureus.88561">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/pdf/cureus-0017-00000088561.pdf">
<meta name="description" content="Type 2 diabetes (T2D), along with other co-morbidities (hypertension, hyperlipidemia, etc.), causes vascular complications and atherosclerosis, leading to heart or kidney damage. The timely detection of cardiovascular disease (CVD) and chronic ...">
<meta name="og:title" content="Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Type 2 diabetes (T2D), along with other co-morbidities (hypertension, hyperlipidemia, etc.), causes vascular complications and atherosclerosis, leading to heart or kidney damage. The timely detection of cardiovascular disease (CVD) and chronic ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12371295">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.7759/cureus.88561"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/cureus-0017-00000088561.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371295%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12371295/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12371295/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-cureus.png" alt="Cureus logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Cureus" title="Link to Cureus" shape="default" href="http://www.cureus.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Cureus</button></div>. 2025 Jul 22;17(7):e88561. doi: <a href="https://doi.org/10.7759/cureus.88561" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.7759/cureus.88561</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cureus%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Cureus%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Cureus%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Diabetes-Kidney-Heart Continuum and Its Implication on Therapeutic Management</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zargar%20AH%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Abdul Hamid Zargar</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Abdul Hamid Zargar</span></h3>
<div class="p">
<sup>1</sup>
Department of Endocrinology, Centre for Diabetes and Endocrine Care, Srinagar, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zargar%20AH%22%5BAuthor%5D" class="usa-link"><span class="name western">Abdul Hamid Zargar</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Balagopalan%20JP%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Jayagopal Pathiyil Balagopalan</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Jayagopal Pathiyil Balagopalan</span></h3>
<div class="p">
<sup>2</sup>
Department of Cardiology, Lakshmi Hospital, Palakkad, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Balagopalan%20JP%22%5BAuthor%5D" class="usa-link"><span class="name western">Jayagopal Pathiyil Balagopalan</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhattacharyya%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Arpandev Bhattacharyya</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Arpandev Bhattacharyya</span></h3>
<div class="p">
<sup>3</sup>
Department of Diabetes and Endocrinology, Manipal Hospital, Bengaluru, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bhattacharyya%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arpandev Bhattacharyya</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Almeida%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Alan Almeida</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Alan Almeida</span></h3>
<div class="p">
<sup>4</sup>
Department of Nephrology, Parmanand Deepchand (PD) Hinduja Hospital and Medical Research Center, Mumbai, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Almeida%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alan Almeida</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Taraphder%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Abhijit Taraphder</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Abhijit Taraphder</span></h3>
<div class="p">
<sup>5</sup>
Department of Nephrology, Apollo Gleneagles Hospital, Kolkata, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Taraphder%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Abhijit Taraphder</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bansal%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sandeep Bansal</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sandeep Bansal</span></h3>
<div class="p">
<sup>6</sup>
Department of Cardiology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bansal%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sandeep Bansal</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dani%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Sameer Dani</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Sameer Dani</span></h3>
<div class="p">
<sup>7</sup>
Department of Cardiology Services, Apollo Cardiovascular and Thoracic Institute, Ahmedabad, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Dani%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sameer Dani</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deka%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Nilakshi Deka</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Nilakshi Deka</span></h3>
<div class="p">
<sup>8</sup>
Department of Endocrinology, Apollo Hospital, Guwahati, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Deka%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Nilakshi Deka</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jain%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Sanjay Jain</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Sanjay Jain</span></h3>
<div class="p">
<sup>9</sup>
Department of Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Jain%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sanjay Jain</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Swami%20OC%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Onkar C Swami</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Onkar C Swami</span></h3>
<div class="p">
<sup>9</sup>
Department of Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Swami%20OC%22%5BAuthor%5D" class="usa-link"><span class="name western">Onkar C Swami</span></a>
</div>
</div>
<sup>9,</sup><sup>✉</sup>
</div>
<div class="cg p">Editors: <span class="name western">Alexander Muacevic</span>, <span class="name western">John R Adler</span>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff-1">
<sup>1</sup>
Department of Endocrinology, Centre for Diabetes and Endocrine Care, Srinagar, IND </div>
<div id="aff-2">
<sup>2</sup>
Department of Cardiology, Lakshmi Hospital, Palakkad, IND </div>
<div id="aff-3">
<sup>3</sup>
Department of Diabetes and Endocrinology, Manipal Hospital, Bengaluru, IND </div>
<div id="aff-4">
<sup>4</sup>
Department of Nephrology, Parmanand Deepchand (PD) Hinduja Hospital and Medical Research Center, Mumbai, IND </div>
<div id="aff-5">
<sup>5</sup>
Department of Nephrology, Apollo Gleneagles Hospital, Kolkata, IND </div>
<div id="aff-6">
<sup>6</sup>
Department of Cardiology, Vardhman Mahavir Medical College and Safdarjung Hospital, Delhi, IND </div>
<div id="aff-7">
<sup>7</sup>
Department of Cardiology Services, Apollo Cardiovascular and Thoracic Institute, Ahmedabad, IND </div>
<div id="aff-8">
<sup>8</sup>
Department of Endocrinology, Apollo Hospital, Guwahati, IND </div>
<div id="aff-9">
<sup>9</sup>
Department of Medical Services, Alembic Pharmaceuticals Ltd., Mumbai, IND </div>
<div class="author-notes p">
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">
Onkar C. Swami <span>onkar.swami@alembic.co.in</span>
</p>
</div>
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Accepted 2025 Jul 22; Collection date 2025 Jul.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025, Zargar et al.</div>
<p>This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12371295</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Type 2 diabetes (T2D), along with other co-morbidities (hypertension, hyperlipidemia, etc.), causes vascular complications and atherosclerosis, leading to heart or kidney damage. The timely detection of cardiovascular disease (CVD) and chronic kidney disease (CKD) risk helps in targeted treatment, thereby reducing hospitalization/death in people with T2D. The vascular complications of T2D, including the onset of CVD or CKD, have been widely studied. However, a clear understanding of the concurrent inter-relatability of diabetes-kidney-heart or diabetes-heart-kidney continuum would further assist the clinicians in preventing morbidity and mortality. The narrative review sought to outline the stages (“prevent,” “regress,” and “retard”), pathophysiological mechanism, and management of the continuum with defined patient profiles and associated risk factors. Pharmacotherapies with a focus on managing both cardiac and renal vascular changes (e.g., sodium-glucose transporter-2 inhibitors {SGLT-2is}, glucagon-like peptide-1 receptor agonists {GLP-1RA}, dipeptidyl peptidase-4 inhibitors {DPP-4is}, lipid-lowering therapy, and renin-angiotensin-aldosterone system {RAAS} blockers) have been discussed. In addition, new diagnostic approaches such as levels of B‐type natriuretic peptide (BNP), N‐terminal prohormone, cardiac troponin, cystatin C, and single-cell transcriptome sequencing, with proven accuracy for detecting vascular complications in the heart and kidney, have been summarized. The review underscores the importance of the early detection of the vascular complications in T2D with individual risk stratification for the initiation/continuation/switching of therapies, to enhance treatment adherence and outcomes.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> cardiovascular disease, chronic kidney disease, diabetes, dyslipidemia, guideline recommendations, pharmacotherapy</p></section></section><section id="sec1"><h2 class="pmc_sec_title">Introduction and background</h2>
<p>Diabetes mellitus (DM) is a fast-growing major health problem, turning into a worldwide crisis with a global estimation of 537 million (in 2021, by the International Diabetes Federation). The number is further expected to rise to 783 million in 2045 [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. Countries such as China, India, the USA, Pakistan, and Brazil have been the epicenters of diabetes in the last decade [<a href="#REF2" class="usa-link" aria-describedby="REF2">2</a>]. The overlapping co-morbid conditions of diabetes, hypertension, and dyslipidemia lead to atherosclerosis, endothelial dysfunction, structural remodeling, and vascular damage that cause cardiovascular diseases (CVDs) through microvascular and macrovascular complications [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>]. The microvascular complications driven by hyperglycemia-induced oxidative stress, high vascular permeability, polyol accumulation, and tissue damage by advanced glycation end products (AGEs) develop diabetic kidney disease (DKD). The latter progresses to CVDs, with heart failure (HF) being the common outcome [<a href="#REF3" class="usa-link" aria-describedby="REF3">3</a>,<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. A monotonic increase in cardiovascular (CV) events, predominantly HF, is related to a decline in estimated glomerular filtration rate (eGFR) among people with type 2 diabetes (T2D) and chronic kidney disease (CKD) [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. The change in eGFR in HF is attributable to longer vasoconstriction, low cardiac output, neurohumoral stimulation, and aggressive diuresis [<a href="#REF6" class="usa-link" aria-describedby="REF6">6</a>]. This impaired kidney or heart function in people with diabetes affects the function of the other, known as cardiorenal syndrome [<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. The concurrent existence of CVD, CKD, and T2D ultimately results in increased morbidity and mortality [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>].</p>
<p>Glycemic control and the adequate management of elevated blood pressure (BP) and lipid levels have been suggested to increase life expectancy [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. Given the heterogeneity in people with diabetes (hypertension or any other co-morbidities, CVD risk, metabolic syndrome, etc.), the management of cardiac and renal complications in such a population must be initiated by prioritizing their clinical profile [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>,<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. There is an immediate need for focused research in key areas, including mechanisms linking metabolic syndrome with CVD and kidney dysfunction, associated risks, risk severity, and therapeutic decisions considering the risk factors [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Although the mechanism of T2D-initiated CVD or CKD onset has been widely studied, research on the vicious cycle consisting of these three entities that further affect or worsen the clinical outcomes is not well-established. Therefore, the rationale underpinning the study is to understand the link between diabetes, kidney, and heart functions. The narrative review sought to evaluate the pathophysiological mechanism of the diabetes-kidney-heart or diabetes-heart-kidney continuum and their global prevalence. Additionally, the efficacy and safety of different classes of pharmacotherapy in reference to clinical studies and guideline recommendations were summarized for the prevention and management of cardiorenal complications in people with coexisting diabetes, hypertension, and dyslipidemia.</p>
<p>Methodology</p>
<p>A comprehensive literature search was conducted for the inclusion of relevant studies (guideline/systematic review and meta-analysis/controlled trial/research article {prospective/retrospective/observational/cohort/post hoc analysis/cross-sectional study} and review article {consensus/comprehensive report/presidential advisory/narrative review}) on T2D, CVD, and CKD, published between 2014 and 2025. Briefly, the following combinations of keywords were used in PubMed and Google Scholar: cardiovascular disease, cardiorenal continuum, chronic kidney disease, diabetes, diagnostic tools, dyslipidemia, guideline recommendations, and pharmacotherapy.</p>
<p>The articles were independently screened by two authors, and the selection was later approved by all authors. Animal/molecular/in vitro studies, as well as protocol/conference proceeding/only abstract/short communication/editorial letter and articles not in the English language, were excluded. A total of 116 full-text articles were included, comprising 33 systematic reviews and meta-analyses, 35 research articles, 11 guidelines, 19 trials, and 18 review articles.</p></section><section id="sec2"><h2 class="pmc_sec_title">Review</h2>
<p>Diabetes triggers cardiorenal continuum</p>
<p>Epidemiology of Diabetes-Induced Cardiorenal Continuum</p>
<p>According to the Diabetes Atlas 2025, India ranks third in the number of adults with diabetes worldwide. Type 2 diabetes is predominant, with &gt;90% global diabetes cases; 89.8 and 38.6 million Indians had diagnosed and undiagnosed (overwhelmingly T2D) diabetes, respectively, in 2024, with reported 0.33 million overall deaths [<a href="#REF10" class="usa-link" aria-describedby="REF10">10</a>]. Cardiovascular complications alone are responsible for 70% mortality in people with T2D [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>]. The first CV event that occurs in T2D is HF, impacting the health of more than 30% of people [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. Diabetes in older people (≥65 years) results in 68% death due to heart disease and 16% death by stroke [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>]. Scientific evidence gathered from people with T2D across the world (2007-2017) showed 32.2% overall CV events: 29.1%, atherosclerosis; 21.2%, coronary heart disease; 14.9%, HF; 14.6%, angina; 10.0%, myocardial infarction (MI); and 7.6%, stroke. Coronary artery disease (CAD) and stroke were indicated as the cause of death in 9.9% of cases [<a href="#REF11" class="usa-link" aria-describedby="REF11">11</a>]. The reported prevalence of CVD and CKD among people with T2D in the USA was 21.6% and 24.1%, respectively; co-prevalence was 8.6% [<a href="#REF12" class="usa-link" aria-describedby="REF12">12</a>].</p>
<p>The chronic kidney disease that affects two out of every five people with T2D is still understudied in the diabetes setting. With CKD, the risk of major vascular events, stroke, and congenital heart disease (CHD) increases by 1.5-fold and death by twofold [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. Stage 2 CKD (44.3%) was found to be the most common co-morbidity in people with diabetes (especially in older age groups) in the United Arab Emirates and Kuwait, followed by CVD (17.3%), CAD (15%), and HF (0.7%). A combination of CVD and CKD was present in 11.7% of people, while the co-prevalence of CAD and CKD was 9.7% [<a href="#REF8" class="usa-link" aria-describedby="REF8">8</a>]. A population-based survey of two major cities (Delhi and Chennai) in India showed 15.4% prevalence of CKD among people with DM; 47% had CKD with abnormal hemoglobin A1c (HbA1c) and hypertension. This reflected that one of every 12 people living in the largest cities of India has CKD [<a href="#REF14" class="usa-link" aria-describedby="REF14">14</a>]. Diabetic kidney disease is the leading cause of end-stage kidney disease (ESKD) and occurs in approximately 40% of diabetic people [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. Individuals with diabetes are already at higher risk for developing CVD. The further development of DKD results in the onset of CVD in these people [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. The risk of major adverse renal CV events was reported to be 97% in people with diabetes and HF, 93% in diabetes with CKD, 98% in diabetes with MI, and 89% in diabetes with stroke. Although 4/5 people with diabetes were free from CV and renal diseases, people having a history of these complications will eventually develop major adverse renal CV events; hence, preventive measures should be prioritized [<a href="#REF16" class="usa-link" aria-describedby="REF16">16</a>].</p>
<p>Renal Insufficiency in Diabetes Linked With CVD</p>
<p>Hyperglycemia in diabetes is the reason for the microvascular disease of the kidney and the eye, as well as the macrovascular disease of the heart and the brain [<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>]. People with diabetes and a history of CVD or HF are on the verge of developing albuminuria and ESKD, resulting in an increased risk of mortality [<a href="#REF4" class="usa-link" aria-describedby="REF4">4</a>]. Consistent CV events, particularly HF, decline eGFR and affect the kidney functions [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>,<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. On the other hand, a progressive kidney disease may lead to HF and congestion [<a href="#REF7" class="usa-link" aria-describedby="REF7">7</a>]. A contemporary UK cohort witnessed the greatest risk of CVDs with eGFR of &lt;30 mL/minute/1.73 m<sup>2</sup> among people with diabetes and suggested that cardiorenal risk depends on the eGFR status-based CKD progression [<a href="#REF5" class="usa-link" aria-describedby="REF5">5</a>]. A study on 9,340 people with T2D and high risk of CVD reported composite renal outcome in 605, new-onset persistent macroalbuminuria in 376, and persistent doubling of serum creatinine in 184 people. Thirteen people died due to renal disease, and 120 underwent renal replacement therapy [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. A randomized, placebo-controlled trial (Effect of Efpeglenatide on Cardiovascular Outcomes {AMPLITUDE-O} trial; n=4,076) reported that patients with ~15 years of diabetes and a history of CVD had a 21.8% incidence of current kidney disease (eGFR: 25 to &lt;60 mL/minute/1.73 m<sup>2</sup>) [<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>]. The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial reported the incidence of CAD, peripheral artery disease, HF, and reduced eGFR (&lt;60 mL/minute/1.73 m<sup>2</sup>) among 4,072/7,020, 603/7,020, 706/7,020, and 1,819/7,020 people with T2D, respectively [<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>]. In a longitudinal study by Wang et al., the risk of stroke with eGFR was assessed as 75-89 mL/minute/1.73 m<sup>2</sup>, 1.03 (95% CI: 0.90-1.18); 60-74 mL/minute/1.73 m<sup>2</sup>, 1.10 (95% CI: 0.94-1.28); 30-59 mL/minute/1.73 m<sup>2</sup>, 1.35 (95% CI: 1.15-1.59); and 15-29 mL/minute/1.73 m<sup>2</sup>, 1.64 (95% CI: 1.10-2.45), when adjusted for multiple factors. Reduced eGFR was the indicator of CHD and stroke in this study [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>].</p>
<p>Pathophysiological Mechanisms of the Cardiorenal Continuum</p>
<p>The cumulative presence of old age, tobacco use, and hypertension or dyslipidemia confers to CVD emergence. Moreover, risk factors, such as elevated inflammatory markers and asymmetric dimethylarginine (ADMA), low nitric oxide bioavailability, and endothelial dysfunction, are related to atherosclerosis and contribute to renal impairment and CV events [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. Accelerated calcification that occurs in people with CKD and/or diabetes is due to the imbalance of promoters (e.g. AGEs; alkaline phosphatase; apoptosis; bone morphogenetic proteins 2, 4, and 6; bone sialoprotein; calcium; hyperglycemia; inflammatory cytokines; matrix metalloproteinases; osteocalcin; oxidative stress; and phosphate) and inhibitors (e.g., bone morphogenetic protein 7, carbonic anhydrase, magnesium, matrix Gla protein, osteopontin, osteoprotegerin, and pyrophosphate) of calcification that predisposes them to HF and arrhythmias [<a href="#REF21" class="usa-link" aria-describedby="REF21">21</a>]. Coronary artery calcification leads to atherosclerotic CVD (ASCVD) [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Furthermore, in CKD, the elevation of inflammatory markers (e.g., C-reactive protein, D-dimer, fibrinogen, interleukin-6, and tumor necrosis factor α) and vascular/intercellular cell adhesion molecules, as well as the loss of renal mass-induced activation of the renin-angiotensin system (RAS), causes oxidative stress and atherosclerosis [<a href="#REF15" class="usa-link" aria-describedby="REF15">15</a>]. Cardiovascular risk factors result in endothelial dysfunction as indicated by increased BP or albuminuria [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>]. Atherosclerotic vascular damage progresses with the advancement of the cardiorenal process, which in turn increases the overall risk for CVD and CKD. The determinants of renal dysfunction, anemia, secondary hyperparathyroidism, and atherogenic substance accumulation accelerate vascular disease at this stage. In case of the failed prevention of CV damage, CKD advances to overt nephropathy and CVD. Several vascular diseases may occur, including MI, angina, stroke, and renal failure, and subsequently lead to ESKD (Figure <a href="#FIG1" class="usa-link">1</a>) [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>,<a href="#REF23" class="usa-link" aria-describedby="REF23">23</a>].</p>
<figure class="fig xbox font-sm" id="FIG1"><h3 class="obj_head">Figure 1. The cardiorenal continuum.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12371295_cureus-0017-00000088561-i01.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/048d/12371295/bf0d49ab2ee1/cureus-0017-00000088561-i01.jpg" loading="lazy" height="347" width="750" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/FIG1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Credit: author’s own creation</p></figcaption></figure><p>The three clinically pertinent stages of the cardiorenal continuum are as follows [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]: (1) the clinical identification of the risk factors, in which the clinical approach is to “prevent” organ damage; (2) the clinical or laboratory identification of asymptomatic target-organ damage by albuminuria, decline in eGFR, left ventricular hypertrophy, etc., in which the clinical approach is to “regress” organ damage; and (3) symptomatic target-organ damage or established CVD/CKD, in which the clinical approach is “retard” organ damage.</p>
<p>The primary prevention of the CV risk factors, including glycemic control and the management of BP and dyslipidemia, can inhibit atherosclerosis. The secondary prevention or regression of albuminuria (a marker of renal and CV damage) should be targeted by means of suitable therapeutic approaches to delay cardiac and renal damage. Ultimately, palliative care should be provided in the last stage of the continuum [<a href="#REF22" class="usa-link" aria-describedby="REF22">22</a>].</p>
<p>New diagnostics</p>
<p>Asymptomatic left ventricular systolic and diastolic dysfunctions may develop even without established CVD incidence in people with T2D, which further aggravates the condition toward mortality [<a href="#REF24" class="usa-link" aria-describedby="REF24">24</a>]. Therefore, the early recognition of CVD in CKD could be helpful in therapy selection and in reducing CV events, hospitalization, and death. Several diagnostic approaches are available, including electrocardiogram, echocardiography, myocardial scintigraphy, nuclear magnetic resonance, computed tomography, and ambulatory heart rhythm monitoring, for the timely diagnosis and treatment of CVD in high-risk populations [<a href="#REF25" class="usa-link" aria-describedby="REF25">25</a>].</p>
<p>Natriuretic peptides or cardiac troponin are used for the detection of stage B HF (i.e., without symptoms but structural/functional cardiac abnormalities) in people with diabetes for the early implementation of effective therapeutic strategies; serial measurements of both detect people at high risk for incident HF [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]. B‐type natriuretic peptide (BNP) and N‐terminal prohormone BNP (NT‐proBNP) levels may predict the adverse prolonged outcome in individuals who have a history of both known and unknown incidence of HF [<a href="#REF27" class="usa-link" aria-describedby="REF27">27</a>]. High-sensitivity cardiac troponin T of ≥14 ng/L and NT-proBNP of ≥125 pg/mL indicate subclinical HF in people with CV-kidney-metabolic syndrome [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>]. Therefore, a high-risk population with CKD, diabetes, or microalbuminuria is more likely to benefit from natriuretic peptide or high-sensitivity cardiac troponin testing [<a href="#REF26" class="usa-link" aria-describedby="REF26">26</a>]. Acute MI is prevalent among patients with CKD, who could have atypical symptoms and no ST-segment elevation. High diagnostic accuracy in such patients can be obtained with cardiac troponin measurements. Other non-nephrotoxic imaging techniques such as echocardiography, single-photon emission computed tomography, or coronary angiography (after reno-protective treatment) could be used in such kind of patients [<a href="#REF28" class="usa-link" aria-describedby="REF28">28</a>]. However, elevated troponin should not be used as a screening tool for HF as it predicts MI through any mechanism [<a href="#REF29" class="usa-link" aria-describedby="REF29">29</a>]. Deep learning algorithms, annotating two-dimensional videos along with Doppler modalities, can quantify the appropriate functioning of the different cardiac parameters. The automated workflow that generated interpretable annotations when integrated in echocardiograms can detect HF accurately in different cohort ethnicities, similar to the manual measurements [<a href="#REF30" class="usa-link" aria-describedby="REF30">30</a>]. Ghorbani et al. reported that the use of convolutional neural networks on a large Stanford echocardiography database and deep learning applied to echocardiography helped in identifying enlarged left atrium, left ventricular hypertrophy, ejection fraction (EF), left ventricular end systolic and diastolic volumes, and the presence of pacemaker leads and in predicting systemic phenotypes of age, sex, weight, and height [<a href="#REF31" class="usa-link" aria-describedby="REF31">31</a>]. Moreover, mid-regional pro-adrenomedullin biomarker is used for determining the therapeutic effectiveness of any antihypertensive drug in people with CKD and uncontrolled BP [<a href="#REF32" class="usa-link" aria-describedby="REF32">32</a>].</p>
<p>The creatinine equation is generally used in determining eGFR and urinary albumin-to-creatinine ratio (UACR) to predict kidney damage. The addition of cystatin C provides greater accuracy, particularly in people with altered creatinine production/metabolism [<a href="#REF33" class="usa-link" aria-describedby="REF33">33</a>]. In patients with DM, serum cystatin C (cutoff value of 82, sensitivity of 81.4, and specificity of 82.4) can act as a better early marker of DKD, compared to albumin excretion ratio and serum creatinine [<a href="#REF34" class="usa-link" aria-describedby="REF34">34</a>]. Besides the current diagnostic methods for kidney disease, the emergence of liquid biopsy, single-cell transcriptome sequencing, and miRNA analysis helps in detecting early-stage kidney diseases and monitoring the treatment responses. Liquid biopsy examines abnormal kidney function markers, the exosomes, and miRNAs to detect DKD in a less invasive approach than the traditional biopsies. However, their use in routine practice should be validated with clinical research [<a href="#REF35" class="usa-link" aria-describedby="REF35">35</a>].</p>
<p>Therefore, the accurate diagnosis of metabolic risk factors and renal and cardiac dysfunctions is crucial for opting for interventions and preventing the disease progression [<a href="#REF9" class="usa-link" aria-describedby="REF9">9</a>].</p>
<p>A holistic approach for preventing the diabetes-kidney-heart continuum</p>
<p>The management of CV-kidney-metabolic health through selecting risk prediction algorithms and holistic approaches among the growing array of healthcare therapies, especially in the three stages of the continuum, needs proper guidance.</p>
<p>Optimal Glycemic Control</p>
<p>Improved glycemic control reduces the occurrence of diabetic nephropathy [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. The conventional DKD management strategies include lifestyle modification along with BP control with the four pillars, the RAS blockers, sodium-glucose transporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RA), and non-steroidal mineralocorticoid receptor antagonists (MRAs) [<a href="#REF36" class="usa-link" aria-describedby="REF36">36</a>]. Landmark studies on diabetes and CVDs have supported therapeutic management with SGLT-2is, GLP-1RAs, dipeptidyl peptidase-4 inhibitors (DPP-4is), and other antidiabetic drugs, as discussed below.</p>
<p>Sodium-Glucose Transporter-2 Inhibitors</p>
<p>The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommended SGLT-2i (and metformin) to be used as the first-line treatment for preventing CV events in patients with T2D and CKD, if eGFR (≥20 mL/minute/1.73 m<sup>2</sup>) allows [<a href="#REF37" class="usa-link" aria-describedby="REF37">37</a>,<a href="#REF38" class="usa-link" aria-describedby="REF38">38</a>]. It provides reno-protection by reducing the decline in eGFR and preventing the new onset and regression of macroalbuminuria [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. A network meta-analysis on patients with T2D found a remarkable effect of dapagliflozin and canagliflozin on renal and CV outcomes and in reducing all-cause mortality, independent of gender [<a href="#REF17" class="usa-link" aria-describedby="REF17">17</a>]. A meta-analysis recorded a notable reduction in risk for CV death with empagliflozin, low risk for major adverse CV events (MACE) and the emergence or progression of kidney disease with canagliflozin, and reduced risk for hospitalization for HF (hHF) with dapagliflozin in patients with T2D [<a href="#REF39" class="usa-link" aria-describedby="REF39">39</a>].</p>
<p>The SCORED trial (n=19,188) revealed that sotagliflozin lowered the risk of CV events in subjects with T2D, CKD (median eGFR: 44.5 mL/minute/1.73 m<sup>2</sup>) and additional CV risks [<a href="#REF40" class="usa-link" aria-describedby="REF40">40</a>]. Empagliflozin, given together with standard care in people (n=4,687) with T2D and established CVD, decreased the rate of CV death and nonfatal MI or stroke [<a href="#REF20" class="usa-link" aria-describedby="REF20">20</a>]. However, the effects of SGLT-2is vary by patient profile as maximum benefits in reducing HF were noted in people with lower eGFR, whereas moderate benefits on MACE were reported in people with established ASCVD [<a href="#REF41" class="usa-link" aria-describedby="REF41">41</a>].</p>
<p>Dapagliflozin reduced kidney failure, CV death, or hHF in individuals with or without T2D (DAPA-CKD trial; n=4,304), independent of HF history [<a href="#REF42" class="usa-link" aria-describedby="REF42">42</a>]. The DAPA-HF trial (n=4,744) on patients with HF (class II/III/IV and EF of ≤40%) and with or without T2D reported the reduced risk of worsening HF or death from CV causes with dapagliflozin treatment, provided in addition to the recommended therapy [<a href="#REF43" class="usa-link" aria-describedby="REF43">43</a>]. Similarly, patients with HF (class II/III/IV and EF of ≤40%, with or without DM) of the EMPEROR-Reduced trial (n=3,730) showed a lower risk of CV death or hHF with empagliflozin, given together with recommended HF treatment [<a href="#REF44" class="usa-link" aria-describedby="REF44">44</a>]. Patients with diabetes and recent worsening HF of the SOLOIST-WHF trial (n=1,222) demonstrated low CV deaths and hHF with sotagliflozin therapy when initiated pre- or post-discharge [<a href="#REF45" class="usa-link" aria-describedby="REF45">45</a>]. Sodium-glucose transporter-2 inhibitors are generally well-tolerated but often result in adverse events that are mostly manageable and do not require treatment discontinuation. A systematic review reported diarrhea with the use of sotagliflozin; diabetic ketoacidosis with sotagliflozin and canagliflozin; acute kidney injury (AKI) and acute kidney failure with empagliflozin; and genital infections, volume depletion, and lower limb amputations with empagliflozin and canagliflozin [<a href="#REF1" class="usa-link" aria-describedby="REF1">1</a>].</p>
<p>Glucagon-Like Peptide-1 Receptor Agonists</p>
<p>In case the HbA1c goal is not achieved with the first-line therapy, then GLP-1RA (dulaglutide) can be considered in obese (type 2) people with diabetes but without congestive HF. However, the co-administration of GLP-1RA with insulin or sulfonylurea is not advisable to avoid the incidence of hypoglycemia [<a href="#REF46" class="usa-link" aria-describedby="REF46">46</a>]. A network meta-analysis of 12 trials reported a lower risk of kidney-specific composite outcome and worsening albuminuria with dual glucose-dependent insulinotropic polypeptide/GLP-1RA (tirzepatide) in patients with T2D [<a href="#REF47" class="usa-link" aria-describedby="REF47">47</a>]. Glucagon-like peptide-1 receptor agonists result in decreased CV death, stroke, or MI [<a href="#REF48" class="usa-link" aria-describedby="REF48">48</a>], along with reduced all-cause mortality, hHF, and risk of kidney dysfunction in people with T2D [<a href="#REF48" class="usa-link" aria-describedby="REF48">48</a>,<a href="#REF49" class="usa-link" aria-describedby="REF49">49</a>]. A post hoc analysis on T2D patients, who were at high risk of CVD, has shown a greater risk of MACE with kidney impairment than without. A reduction in HbA1c with semaglutide regardless of baseline eGFR (&lt;45 and ≥45 to &lt;60 mL/minute/1.73 m<sup>2</sup>) and UACR (≥30 mg/g) indicated its CV benefits [<a href="#REF50" class="usa-link" aria-describedby="REF50">50</a>].</p>
<p>The Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial of lixisenatide (given in addition to the usual care, n=3,031) in people with T2D, macroalbuminuria, and recent coronary event found a decrease in UACR [<a href="#REF51" class="usa-link" aria-describedby="REF51">51</a>]. Efpeglenatide, another GLP-1RA, reduces the risk of CV events among people with T2D, a history of CVD or current kidney disease, and one other CV risk factor [<a href="#REF19" class="usa-link" aria-describedby="REF19">19</a>]. Sodium-glucose transporter-2 inhibitors and GLP-1RA can be used in case of CVD or renal complications [<a href="#REF52" class="usa-link" aria-describedby="REF52">52</a>]. Using exenatide and SGLT-2i in parallel or in relatively close sequence has shown benefits on mortality, as well as CV and renal outcomes in patients with T2D and a history of CVD and HF (EXSCEL trial, n=14,752) [<a href="#REF53" class="usa-link" aria-describedby="REF53">53</a>].</p>
<p>In the LEADER trial (n=4,668), liraglutide (added to standard care) showed a notable reduction in the primary composite outcome, including CV death, nonfatal MI, or stroke among patients with T2D and established CVD and/or CKD stage 3 or higher [<a href="#REF54" class="usa-link" aria-describedby="REF54">54</a>]. The reduced risk of DKD progression and the low rate of the new onset of macroalbuminuria were reported with liraglutide treatment in T2D patients with eGFR of 15 to &lt;30 mL/minute/1.73 m<sup>2</sup> and a high risk of CVD (n=4,668), who were already receiving the usual care. Increase in UACR was less (17%) with the treatment [<a href="#REF18" class="usa-link" aria-describedby="REF18">18</a>]. Similarly, in people with T2D and established CVD and/or CKD stage of ≥3 (SUSTAIN-6 trial, n=1,648), semaglutide (on top of standard care) was reported to lower the rate of CV death and nonfatal MI or stroke [<a href="#REF55" class="usa-link" aria-describedby="REF55">55</a>]. A systematic review and meta-analysis on GLP-1RAs demonstrated improvements in glycemic control, weight reduction, and CV outcomes among individuals with T2D and advanced CKD and ESKD; however, the rate of gastrointestinal side effects such as nausea and vomiting was higher [<a href="#REF56" class="usa-link" aria-describedby="REF56">56</a>].</p>
<p>Dipeptidyl Peptidase-4 Inhibitors</p>
<p>Dipeptidyl peptidase-4 inhibitors, linagliptin and saxagliptin, provide reno-protection apart from glycemic control [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. A systematic review and meta-analysis of 17 randomized controlled trials supported the use of DPP-4is (sitagliptin/vildagliptin/alogliptin/linagliptin) in patients with T2D and the presence or absence of albuminuria, as they potentially reduce UACR and decline in eGFR [<a href="#REF57" class="usa-link" aria-describedby="REF57">57</a>]. Another systematic review and meta-analysis (of eight randomized controlled trials) found no improvement in eGFR or mortality in patients with T2D but retard albuminuria progression with 52 weeks of DPP-4i therapy [<a href="#REF58" class="usa-link" aria-describedby="REF58">58</a>].</p>
<p>Sitagliptin added to the usual care showed a lower risk of MACE, hHF, or death in people (n=7,332) with T2D and established CVD of the TECOS study [<a href="#REF59" class="usa-link" aria-describedby="REF59">59</a>]. Moreover, data from the Taiwan National Health Insurance Research Database (n=3,750) showed that the risk of CV death, nonfatal MI or stroke, and hHF was not increased with vildagliptin in patients with T2D (n=1,250) having recent acute ischemic stroke or coronary syndrome [<a href="#REF60" class="usa-link" aria-describedby="REF60">60</a>]. In patients (n=7,348) with DM and AKI (eGFR: 70.5±35.5 mL/minute/1.73 m<sup>2</sup>), DPP-4i treatment resulted in the decreased risk of mortality, MACEs, major adverse kidney events (MAKEs), and re-dialysis [<a href="#REF61" class="usa-link" aria-describedby="REF61">61</a>].</p>
<p>The CARMELINA trial on people with T2D and nephrotic-range proteinuria (baseline UACR of &gt;2,200 mg/g creatinine with any eGFR) showed a reduction in albuminuria and HbA1c with linagliptin and standard of care treatment; the therapy did not affect the CV or kidney risks [<a href="#REF62" class="usa-link" aria-describedby="REF62">62</a>]. Sitagliptin, when administered to 205 patients with T2D, CKD, or ESKD (on hemodialysis) and hospitalized for acute MI, resulted in no increase in CV death, ischemic stroke, or hHF risks [<a href="#REF63" class="usa-link" aria-describedby="REF63">63</a>].</p>
<p>Other Antidiabetic Drugs</p>
<p>In people with T2D, risks of hypoglycemia and weight gain with insulin and sulfonylurea rendered metformin the drug of choice in reducing the macrovascular risk of MI and CV death [<a href="#REF52" class="usa-link" aria-describedby="REF52">52</a>]. A cohort study on people with T2D and high CV risk (n=12,156) showed lower rates of all-cause mortality with metformin but not the composite endpoint of CV death, MI, or stroke. The findings were most evident in people without prior HF or moderate-to-severe CKD (eGFR: ≤45 mL/minute/1.73 m<sup>2</sup>) [<a href="#REF64" class="usa-link" aria-describedby="REF64">64</a>]. A retrospective cohort study reported reduced risk of diabetic nephropathy, MACE, and MAKEs with the use of metformin [<a href="#REF65" class="usa-link" aria-describedby="REF65">65</a>]. The EDGE study in patients (n=66) with T2D reported a similar effect of ɑ-glucosidase inhibitor (voglibose) and sitagliptin in improving endothelial dysfunction. The study reported diarrhea, edema, nausea, and abdominal fullness after 12 weeks of voglibose treatment [<a href="#REF66" class="usa-link" aria-describedby="REF66">66</a>]. The thiazolidinedione drug class (particularly pioglitazone) is responsible for lowering HbA1c and CV events and for improving insulin sensitivity in T2D [<a href="#REF52" class="usa-link" aria-describedby="REF52">52</a>]. As insulin clearance is carried out by the kidneys, reduced eGFR in CKD may result in hypoglycemia; hence, the modifications of insulin should be contemplated to reach glycemic targets [<a href="#REF46" class="usa-link" aria-describedby="REF46">46</a>]. Additionally, insulin therapy is believed to be associated with increased risk of ASCVD and hypoglycemia [<a href="#REF52" class="usa-link" aria-describedby="REF52">52</a>]. The reason could be the insulin resistance in people with T2D, receiving insulin therapy. A retrospective real-world study on hospitalized patients with T2D (n=2,356) reported insulin therapy linked to a high risk of carotid atherosclerotic plaque, including macrovascular complications, even after adjusting for the CV risk factors [<a href="#REF67" class="usa-link" aria-describedby="REF67">67</a>].</p>
<p>The low risk of all-cause mortality and CV events was found with metformin in people with T2D and mild or moderate CKD (eGFR: ≥30 mL/minute/1.73 m<sup>2</sup>) [<a href="#REF68" class="usa-link" aria-describedby="REF68">68</a>]. However, in mild-to-moderate CKD, the use of metformin should be expanded with caution depending on the eGFR and regular follow-up of kidney function [<a href="#REF69" class="usa-link" aria-describedby="REF69">69</a>]. Additionally, thiazolidinedione may improve glycemic control similar to other antidiabetic medications in patients with diabetes and renal dysfunction [<a href="#REF70" class="usa-link" aria-describedby="REF70">70</a>].</p>
<p>The Food and Drug Administration (FDA) has approved the use of metformin in individuals with HF (in 2006), as well as with kidney disease (in 2016) [<a href="#REF52" class="usa-link" aria-describedby="REF52">52</a>]. The retrospective cohort study by Yi et al. reported lower risks of MACEs and MAKEs in CKD patients (stages 3A, 3B, and 4) with the continuous use of metformin than no or discontinued use [<a href="#REF65" class="usa-link" aria-describedby="REF65">65</a>]. However, prolonged metformin use-associated adverse effects are diarrhea, bloating, abdominal cramping, and vitamin B12 deficiency [<a href="#REF46" class="usa-link" aria-describedby="REF46">46</a>]. Sulfonylureas and DPP-4is are the most commonly used glucose-lowering treatments in patients with T2D and advanced CKD (stages 3b-5). A real-world study on this population reported similar safety profiles of DPP-4i (n=1,204) and sulfonylureas (n=1,204) regarding renal and CV outcomes and all-cause mortality. However, different DPP-4is are preferred over sulfonylureas due to a lower risk of hospitalized hypoglycemia and all-cause mortality [<a href="#REF71" class="usa-link" aria-describedby="REF71">71</a>]. Thiazolidinediones can be used in CKD as they are not cleared by the kidney, but fluid retention is a major adverse effect; therefore, the drug should not be used in advanced HF [<a href="#REF46" class="usa-link" aria-describedby="REF46">46</a>].</p>
<p>Lipid-Lowering Therapy</p>
<p>The management of low-density lipoprotein-cholesterol (LDL-C) is the primary therapeutic goal in people with ASCVD. Besides LDL-C, the management of non-high-density lipoprotein-cholesterol (HDL-C) is particularly recommended in the Indian population by the Lipid Association of India. The recommended targets for LDL-C and non-HDL-C are &lt;50 mg/dL and &lt;70 mg/dL, respectively, in people with T2D and CVD or ≥2 additional major CV risk factors [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>].</p>
<p>Statin and Non-statin Agents</p>
<p>In case of very high triglyceride levels (&gt;500 mg/dL), fibrates and omega-3 fatty acids could be considered, followed by statin therapy to reach the LDL-C and non-HDL-C targets [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>]. In addition, bile acid sequestrants are used for lowering cholesterol and improving glycemic control in people with impaired liver and kidney function due to their low systemic toxicity rate [<a href="#REF72" class="usa-link" aria-describedby="REF72">72</a>]. Cholesterol-lowering therapy with bempedoic acid helps in reducing CV risk in people with diabetes (with/without CVD), as evidenced by the Cholesterol Lowering via Bempedoic Acid (CLEAR) trial (n=13,970) [<a href="#REF73" class="usa-link" aria-describedby="REF73">73</a>]. Advanced lipid-lowering therapies such as proprotein convertase subtilisin-kexin type 9 (PCKS9) inhibitors, particularly in combination with statins, have higher LDL-C target achievement rates in T2D patients [<a href="#REF74" class="usa-link" aria-describedby="REF74">74</a>].</p>
<p>Fibrates are beneficial in people with moderate CKD and co-morbidities (DM, hypertension, atrial fibrillation, peripheral artery disease, HF, MI, and stroke), who had never received statin or other lipid-lowering agents to reduce CV events by decreasing triglycerides and increasing HDL-C levels [<a href="#REF75" class="usa-link" aria-describedby="REF75">75</a>]. A meta-analysis of 21 randomized studies observed that fibrates alone or with statin reduced albuminuria progression and increased albuminuria regression in people with/without diabetes and mild CKD [<a href="#REF76" class="usa-link" aria-describedby="REF76">76</a>]. In CKD patients, PCKS9 inhibitors reduce LDL-C and CV events, when added to existing statin therapy; however, their safety and efficacy in severe CKD and ESKD are not established [<a href="#REF77" class="usa-link" aria-describedby="REF77">77</a>]. A meta-analysis of 19 randomized trials reported reduced CV morbidity in secondary-prevention patients having a history of ASCVD (CAD, peripheral artery disease, or cerebrovascular disease) with intensified statin therapy alone or added to PCSK9 inhibitors or ezetimibe [<a href="#REF78" class="usa-link" aria-describedby="REF78">78</a>]. Statin intolerance and ezetimibe side effects led to the use of PCSK9 inhibitors for the secondary prevention of patients with CV risk factors and established CVD, who achieved the recommended LDL-C targets with the therapy [<a href="#REF79" class="usa-link" aria-describedby="REF79">79</a>]. Moreover, a meta-analysis of five randomized trials emphasized non-statin lipid-lowering therapy with a small-interfering RNA, inclisiran, that reduces LDL-C, PCSK9, and total cholesterol levels in individuals with ASCVD [<a href="#REF80" class="usa-link" aria-describedby="REF80">80</a>]. Inclisiran is approved by the FDA and the European Medicines Agency. This cholesterol-lowering therapy was reported to alter total cholesterol, HDL-C, non-HDL-C, apolipoprotein B, and lipoprotein(a) and decrease pre-specified CV endpoints (cardiac death, signs or symptoms of cardiac arrest, nonfatal MI, or stroke) at 18 months [<a href="#REF81" class="usa-link" aria-describedby="REF81">81</a>].</p>
<p>A nested case-control study on 15,830 patients with CKD recorded a reduced risk of MACE with current fibrate use (especially pemafibrate) and suggested its effective use in CKD patients with eGFR of 15-30 mL/minute/1.73 m<sup>2</sup> [<a href="#REF82" class="usa-link" aria-describedby="REF82">82</a>]. A meta-analysis of 14 trials on dialysis patients reported a reduction in triglyceride and LDL-C levels with omega-3 supplementation but no change in total cholesterol, HDL-C, and albumin levels [<a href="#REF83" class="usa-link" aria-describedby="REF83">83</a>]. In addition, bile acid sequestrants can be used in T2D and ESKD together with metformin and statin due to their non-absorbable nature; however, associated gastrointestinal adverse events, especially constipation, should be considered [<a href="#REF72" class="usa-link" aria-describedby="REF72">72</a>]. The FOURIER trial (n=27,564) on individuals with atherosclerosis and advanced CKD demonstrated greater reduction in the composite of CV death, MI, and stroke with evolocumab (PCSK9 inhibitor) treatment [<a href="#REF84" class="usa-link" aria-describedby="REF84">84</a>].</p>
<p>Nicotinic Acid</p>
<p>Lipid-lowering agent niacin alone or in combination with statin significantly improved the lipid profile of patients with T2D, but long-term use increased fasting plasma glucose. Hence, regular glucose monitoring is required during long-term treatment [<a href="#REF85" class="usa-link" aria-describedby="REF85">85</a>]. A meta-analysis of 11 randomized trials concluded that niacin provides CV benefits when added to ongoing statin therapy; however, it is associated with a 35% risk of developing diabetes [<a href="#REF86" class="usa-link" aria-describedby="REF86">86</a>]. The 2025 American Diabetes Association (ADA) “Standards of Care in Diabetes” recommended not to use niacin-statin combination therapy due to the high risk of stroke, with additional side effects and additional CV benefits compared to statin therapy [<a href="#REF87" class="usa-link" aria-describedby="REF87">87</a>].</p>
<p>Blood Pressure and Albuminuria Control: Renin-Angiotensin-Aldosterone System (RAAS) Blockers</p>
<p>The renin-angiotensin-aldosterone system (RAAS) plays a crucial role in BP control and renal functioning, particularly in slowing DKD progression and lowering proteinuria and the risk of overt nephropathy. The reno-protective effects of the RAAS blockers support their use in hypertension and CKD, especially when people have proteinuria [<a href="#REF88" class="usa-link" aria-describedby="REF88">88</a>].</p>
<p>Angiotensin-Converting Enzyme Inhibitors (ACEis) and Angiotensin Receptor Blockers (ARBs)</p>
<p>Angiotensin-converting enzyme inhibitors (ACEis) reduce all-cause and CV mortalities, as well as MACE in people with DM; on the contrary, angiotensin receptor blocker (ARB) has no such benefits on CV outcomes [<a href="#REF89" class="usa-link" aria-describedby="REF89">89</a>]. A cohort study on people with diabetes found comparable effects of ACEi (n=34,043) and ARB (n=23,772) on hospitalization for AKI or hyperkalemia, long-term dialysis, and all-cause, CV, and non-CV deaths [<a href="#REF90" class="usa-link" aria-describedby="REF90">90</a>]. Another cohort study found similar effects of ACEi (n=55) and ARB (n=68) on UACR in people with hypertension and T2D; slightly increased eGFR was recorded with ARB, compared to ACEi [<a href="#REF91" class="usa-link" aria-describedby="REF91">91</a>]. The antiarrhythmic effects of ARBs are obtained through alterations of ion channel activity, refractoriness, and sympathetic tone and the inhibition of angiotensin II activity in the left atrium. This in turn affects the atrial stretch, inflammation, interstitial fibrosis, and structural remodeling and consequently the persistence and recurrence of atrial fibrillation. Telmisartan has a promising role in preventing paroxysmal to persistent atrial fibrillation [<a href="#REF92" class="usa-link" aria-describedby="REF92">92</a>]. Therefore, in people with diabetes and hypertension, choices of ARBs are telmisartan and losartan for reducing CV risk factors [<a href="#REF93" class="usa-link" aria-describedby="REF93">93</a>].</p>
<p>Among people with CVD or CKD, ACEi provides additional reno-protective effects against long-term dialysis, compared to ARBs [<a href="#REF90" class="usa-link" aria-describedby="REF90">90</a>]. Similarly, in CKD patients of a 15-year cohort study, a lower incidence of ESKD (1.39% versus 2.34%, p=0.008) was noticed with ACEi (n=6,898) treatment than ARB (n=12,758); the result was similar (0.30% versus 0.37%, p=0.11) in those without CKD. However, the ACEi group reported a higher risk of stroke than the ARB group [<a href="#REF94" class="usa-link" aria-describedby="REF94">94</a>]. In patients with DM and albuminuria, both ACEis and ARBs reduced the doubling of serum creatinine; however, ARBs were preferred for reducing the risk of ESKD by 23% [<a href="#REF95" class="usa-link" aria-describedby="REF95">95</a>]. Monotherapy or combination therapy of ARB demonstrated optimum BP control and improved proteinuria in people with hypertension and CKD, with or without diabetes [<a href="#REF88" class="usa-link" aria-describedby="REF88">88</a>]. Telmisartan is the preferred ARB in people with a history of atrial fibrillation, while losartan is recommended in people at a higher risk of stroke [<a href="#REF93" class="usa-link" aria-describedby="REF93">93</a>].</p>
<p>In patients with peritoneal dialysis, ACEis and ARBs reduce the loss of residual renal function, though in dialysis patients, the RAS blockers do not reduce CV events [<a href="#REF96" class="usa-link" aria-describedby="REF96">96</a>]. A cohort study (nationwide Korean Heart Failure registry) on moderate-to-severe CKD patients, hospitalized for acute HF (n=1,601), reported a reduction in one-year mortality and HF readmission with the initiation of ACEi or ARB treatment at discharge. The study also suggested considering RAS blockers in people with above-moderate renal insufficiency but not with ESKD [<a href="#REF97" class="usa-link" aria-describedby="REF97">97</a>].</p>
<p>Mineralocorticoid Receptor Antagonists</p>
<p>Mineralocorticoid receptor antagonists improve arterial stiffness and endothelial function by exerting beneficial effects on pulse wave velocity, augmentation index, and flow-mediated dilation [<a href="#REF98" class="usa-link" aria-describedby="REF98">98</a>]. In patients with hypertension and DM or overt albuminuria or proteinuria, the combination therapy of MRA with RAS blocker reduces BP and UACR but results in slightly elevated potassium concentrations [<a href="#REF99" class="usa-link" aria-describedby="REF99">99</a>].</p>
<p>Non-steroidal MRAs reduce BP, the risk of composite kidney, and CV outcomes and help in the remission of proteinuria and hence can be used for cardiorenal protection in people with CKD [<a href="#REF100" class="usa-link" aria-describedby="REF100">100</a>]. Finerenone, an MRA, reduces the risk of MACE, the progression of kidney disease, and hHF in people with established T2D and ASCVD [<a href="#REF101" class="usa-link" aria-describedby="REF101">101</a>]. Other studies reported similar findings of finerenone in people with T2D and CKD [<a href="#REF102" class="usa-link" aria-describedby="REF102">102</a>,<a href="#REF103" class="usa-link" aria-describedby="REF103">103</a>].</p>
<p>The American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) clinical guideline (2022) recommended MRA (spironolactone or eplerenone) in HF with reduced EF (classes II-IV), eGFR of &gt;30 mL/minute/1.73 m<sup>2</sup>, and serum potassium of &lt;5.0 mEq/L to reduce morbidity and mortality [<a href="#REF104" class="usa-link" aria-describedby="REF104">104</a>]. The 2023 European Society of Cardiology (ESC) guideline also recommended MRAs for patients having HF with reduced EF and diabetes to reduce the risk of hHF and death [<a href="#REF105" class="usa-link" aria-describedby="REF105">105</a>]. The FINEARTS-HF trial on 6,001 patients with HF (left ventricular EF of ≥40%) reported a reduction in CV death and the worsening of HF events with finerenone treatment concomitantly used with SGLT-2i [<a href="#REF106" class="usa-link" aria-describedby="REF106">106</a>]. Among older patients with HF and DM or acute renal insufficiency, MRA reduced the risk of hHF but was associated with a high risk of hyperkalemia and acute renal insufficiency, particularly in those with preserved EF. This indicated the limited safety of MRAs in the older population [<a href="#REF107" class="usa-link" aria-describedby="REF107">107</a>]. Therefore, routine potassium monitoring and dose reduction or the temporary discontinuation of finerenone can be opted for protecting the renal and CV systems from hyperkalemia [<a href="#REF108" class="usa-link" aria-describedby="REF108">108</a>].</p>
<p>Strategies to Improve Treatment Adherence</p>
<p>Despite the availability of evidence-based recommendations, factors such as high prescription costs and insufficient guidance from healthcare professionals may negatively impact adherence to a treatment, as well as the health of the community. Therefore, reduction in healthcare cost and easy accessibility to healthcare providers need to garner the same attention as research, in the real-world setting [<a href="#REF109" class="usa-link" aria-describedby="REF109">109</a>]. The FDA focused on ways to improve the appropriate use of the approved medications that include access to generic medications, the active monitoring of regulated products, health literacy, medication guides, and public workshops for providing up-to-date product information [<a href="#REF110" class="usa-link" aria-describedby="REF110">110</a>]. Another approach can be considering single-tablet combination therapies for improving patient adherence and clinical outcomes while providing economic advantages [<a href="#REF111" class="usa-link" aria-describedby="REF111">111</a>]. Moreover, patient-centered education and patient-reported experience or perception may aid in developing new routines to improve treatment adherence [<a href="#REF112" class="usa-link" aria-describedby="REF112">112</a>].</p>
<p>Guideline recommendations for preventing and managing cardiorenal complications in patients with diabetes</p>
<p>In patients with T2D and established CVD or high CV risk, the 2022 ACC/AHA/HFSA guideline recommended treatment with SGLT-2i for the prevention of hHF [<a href="#REF104" class="usa-link" aria-describedby="REF104">104</a>]. The ADA clinical practice recommendations (2025) suggested GLP-1RA and SGLT-2i combination therapy in people with T2D and those with the risk of or established ASCVD to reduce adverse CV risk and renal events [<a href="#REF87" class="usa-link" aria-describedby="REF87">87</a>]. On the contrary, the 2023 ESC guidelines expressed their reservation on the use of GLP-1RA and SGLT-2i combination therapy for obtaining favorable cardiorenal outcomes in patients with T2D [<a href="#REF105" class="usa-link" aria-describedby="REF105">105</a>]. An Indian practice standard and management algorithm indicated ACEis for people with diabetes and stable angina, hypertension, HF, or early CKD. In addition to ACEi, high-intensity statin therapy was also recommended in people with diabetes and stable CAD. Oral antidiabetics such as metformin, gliclazide, gliptins, and empagliflozin were also suggested for this population [<a href="#REF113" class="usa-link" aria-describedby="REF113">113</a>]. The guidelines by the Research Society for the Study of Diabetes in India recommended diabetes treatment depending on hypertension severity, which includes ARB, ACEi, calcium channel blockers, beta blockers, and diuretics (thiazides). Angiotensin receptor blockers are safe and well-tolerated in reducing CV, cerebrovascular, and renal complications; ARBs are suggested over ACEis when BP control is primary in people with diabetes. Angiotensin receptor blocker or ACEi in combination with SGLT-2i has shown better BP control and eGFR in people with T2D [<a href="#REF93" class="usa-link" aria-describedby="REF93">93</a>]. Indian guidance (2018) on CV and renal morbidity management in T2D and KDIGO guideline (2024) recommended ARB or ACEi alone but not in combination for CKD treatment [<a href="#REF13" class="usa-link" aria-describedby="REF13">13</a>,<a href="#REF38" class="usa-link" aria-describedby="REF38">38</a>]. A more detailed guideline recommendation is provided in Table <a href="#TAB1" class="usa-link">1</a>.</p>
<section class="tw xbox font-sm" id="TAB1"><h3 class="obj_head">Table 1. Guideline recommendations for the management of diabetes with cardiovascular and/or renal complications.</h3>
<div class="caption p">
<p>Strong consensus recommendations (based on the level of evidences, as given by the respective guidelines) are highlighted in bold</p>
<p>ACC/AHA, American College of Cardiology/American Heart Association; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel blocker; CVD, cardiovascular disease; CV, cardiovascular; DM, diabetes mellitus; DPP-4i, dipeptidyl peptidase-4 inhibitors; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; ESKD, end-stage kidney disease; GLP-1RA, glucagon-like peptide-1 receptor agonist; HbA1c, hemoglobin A1c; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; hHF, hospitalization for HF; KDIGO, Kidney Disease: Improving Global Outcomes; LDL-C, low-density lipoprotein-cholesterol; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonists; NYHA, New York Heart Association; PCSK9, proprotein convertase subtilisin-kexin type 9; RSSDI, Research Society for the Study of Diabetes in India; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes; UACR, urinary albumin-to-creatinine ratio; MI, myocardial infarction; CKD, chronic kidney disease</p>
</div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr style="background-color:#ccc">
<td rowspan="1" colspan="1">Reference</td>
<td rowspan="1" colspan="1">Guideline</td>
<td rowspan="1" colspan="1">Recommendations for management of DM with CVD and/or kidney disease</td>
</tr>
<tr>
<td rowspan="21" colspan="1">[<a href="#REF87" class="usa-link" aria-describedby="REF87">87</a>,<a href="#REF114" class="usa-link" aria-describedby="REF114">114</a>]</td>
<td rowspan="21" colspan="1">American Diabetes Association Professional Practice Committee (2025)</td>
<td rowspan="1" colspan="1">SGLT-2i and GLP-1RA</td>
</tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i and GLP-1 RA to reduce albuminuria</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i (if eGFR≥20 mL/minute/1.73m<sup>2</sup>) in people with T2D and CKD to reduce CVD risk</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i or GLP-1RA in people with T2D and established ASCVD or renal disease</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i in people with T2D and established HFpEF or reduced HFrEF</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in people with T2D and established ASCVD, multiple ASCVD risk factors, or CKD</td></tr>
<tr><td rowspan="1" colspan="1">Statin/non-statin therapy</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Initiate statin therapy in people with diabetes with ASCVD risk factors, aged 20-39 years, in addition to lifestyle therapy</td></tr>
<tr><td rowspan="1" colspan="1">Moderate-intensity therapy in people with diabetes without ASCVD, aged 40-75 years, in addition to lifestyle therapy</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Moderate-intensity statin therapy in people with diabetes, aged &gt;75 years</td></tr>
<tr><td rowspan="1" colspan="1">High-intensity therapy in people aged 40-75 years with diabetes, LDL-C of ≥70 mg/dL (≥1.8 mmol/L), and ≥1 ASCVD risk factor</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Ezetimibe or PCSK9 inhibitor with maximally tolerated statin therapy in people with diabetes, LDL-C of ≥70 mg/dL (≥1.8 mmol/L), and ASCVD risk, aged 40-75 years</td></tr>
<tr><td rowspan="1" colspan="1">Icosapent ethyl in addition to statin therapy in people with ASCVD or other CV risk factors and controlled LDL-C but elevated triglycerides (150-499 mg/dL), to reduce CV risk</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Other antidiabetic drugs</td></tr>
<tr><td rowspan="1" colspan="1">Metformin in people with T2D and stable HF, if eGFR&gt;30 mL/minute/1.73 m<sup>2</sup>
</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACEi or ARB</td></tr>
<tr><td rowspan="1" colspan="1">First-line therapy for hypertension in people with diabetes and CAD or diabetes and UACR (≥300 mg/g creatinine)</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Combination of ACEi and ARB and combination of ACEi or ARB with direct renin inhibitors are not recommended</td></tr>
<tr><td rowspan="1" colspan="1">MRA</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Non-steroidal MRA (if eGFR≥25 mL/minute/1.73m<sup>2</sup>) in people with T2D and CKD to reduce CVD risk</td></tr>
<tr><td rowspan="1" colspan="1">Non-steroidal MRA in people with T2D and CKD treated with ACEi or ARB (maximum tolerated dose) to improve CV outcomes and reduce the risk of CKD progression</td></tr>
<tr style="background-color:#ccc">
<td rowspan="26" colspan="1">[<a href="#REF105" class="usa-link" aria-describedby="REF105">105</a>]</td>
<td rowspan="26" colspan="1">The ESC guideline (2023)</td>
<td rowspan="1" colspan="1">SGLT-2i and GLP-1RA</td>
</tr>
<tr><td rowspan="1" colspan="1">SGLT-2i in people with T2D with multiple ASCVD risk factors or established ASCVD</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in people with T2D and HFrEF (NYHA classes II-IV) to reduce the risk of hHF and CV death</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i in people with T2D and LVEF of &gt;40%</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in people with T2D and CKD with eGFR of ≥20 mL/minute/1.73 m<sup>2</sup>
</td></tr>
<tr><td rowspan="1" colspan="1">GLP-1RAs in people with T2D at risk of or with HF</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">GLP-1RA in people with diabetes and CKD (eGFR of &gt;15 mL/minute/1.73 m<sup>2</sup>) to achieve adequate glycemic control with low risk of hypoglycemia and beneficial effects on CV risk and albuminuria</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i or GLP-1RA in people with T2D and ASCVD, independent of baseline/target HbA1c and concomitant glucose-lowering medication</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i and GLP-1RA in people with T2D without ASCVD and 10-year CVD risk</td></tr>
<tr><td rowspan="1" colspan="1">DPP-4i</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sitagliptin and linagliptin in people with T2D at risk of or with HF</td></tr>
<tr><td rowspan="1" colspan="1">Saxagliptin is not recommended in people with T2D and at risk of HF or with previous HF</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Statin/non-statin therapy</td></tr>
<tr><td rowspan="1" colspan="1">PCSK9 inhibitor for people with diabetes and at very high CV risk, with persistently high LDL-C levels, despite having statin therapy (maximum tolerated dose) combined with ezetimibe, or having statin intolerance</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Statin/ezetimibe combination in people with diabetes and CKD</td></tr>
<tr><td rowspan="1" colspan="1">Other antidiabetic drugs</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Metformin in people with T2D and ASCVD</td></tr>
<tr><td rowspan="1" colspan="1">Pioglitazone in people with T2D and ASCVD, without HF</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Basal insulins (glargine and degludec) in people with T2D at risk of or with HF</td></tr>
<tr><td rowspan="1" colspan="1">ACEi or ARB</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Sacubitril/valsartan or ACEi in people with T2D and HFrEF (NYHA classes II-IV) to reduce the risk of hHF and death; in case of sacubitril/valsartan or ACEi intolerance, ARBs are recommended</td></tr>
<tr><td rowspan="1" colspan="1">Maximum tolerated dose of an ACEi or ARB in people with diabetes and CKD</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Combination of an ARB and an ACEi is not recommended</td></tr>
<tr><td rowspan="1" colspan="1">MRA</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">MRAs in people with T2D and HFrEF (NYHA classes II-IV) to reduce the risk of hHF and death</td></tr>
<tr><td rowspan="1" colspan="1">Finerenone in addition to ACEi or ARB in people with T2D and eGFR of &gt;60 mL/minute/1.73 m<sup>2</sup> with UACR of ≥300 mg/g or eGFR of 25-60 mL/minute/1.73 m<sup>2</sup> and UACR of ≥30 mg/g</td></tr>
<tr style="background-color:#ccc">
<td rowspan="5" colspan="1">[<a href="#REF115" class="usa-link" aria-describedby="REF115">115</a>]</td>
<td rowspan="5" colspan="1">The ACC/AHA guideline (2019)</td>
<td rowspan="1" colspan="1">SGLT-2i and GLP-1RA</td>
</tr>
<tr><td rowspan="1" colspan="1">SGLT-2i or GLP-1RA in people with T2D and ASCVD risk factors</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Statin therapy</td></tr>
<tr><td rowspan="1" colspan="1">Moderate-intensity statin therapy in adults (40-75 years) with DM, regardless of estimated 10-year ASCVD risk</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">High-intensity statin therapy in adults with DM and multiple ASCVD risk factors</td></tr>
<tr>
<td rowspan="10" colspan="1">[<a href="#REF38" class="usa-link" aria-describedby="REF38">38</a>]</td>
<td rowspan="10" colspan="1">KDIGO guideline (2024)</td>
<td rowspan="1" colspan="1">SGLT-2i and GLP-1RA</td>
</tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in people with T2D, CKD, and eGFR of ≥20 mL/minute/1.73 m<sup>2</sup>
</td></tr>
<tr><td rowspan="1" colspan="1">Long-acting GLP-1RA in adults with T2D and CKD, who have not achieved individualized glycemic targets despite using metformin and SGLT-2i</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Statin therapy</td></tr>
<tr><td rowspan="1" colspan="1">In adults (18-49 years) with CKD but not treated with chronic dialysis or kidney transplantation and with one or more of the following: MI or coronary revascularization, DM, or stroke</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Estimated 10-year incidence of coronary death or nonfatal MI of &gt;10%</td></tr>
<tr><td rowspan="1" colspan="1">ACEi or ARB</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">In people with diabetes and CKD and moderate-to-severe increased albuminuria</td></tr>
<tr><td rowspan="1" colspan="1">MRA</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">In adults with T2D and eGFR of &gt;25 mL/minute/1.73 m<sup>2</sup>, normal serum potassium concentration, and albuminuria (&gt;30 mg/g)</td></tr>
<tr>
<td rowspan="16" colspan="1">[<a href="#REF93" class="usa-link" aria-describedby="REF93">93</a>]</td>
<td rowspan="16" colspan="1">RSSDI guideline (2022)</td>
<td rowspan="1" colspan="1">SGLT-2i</td>
</tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in combination with ACEi and ARB in people with T2D and CKD, to reduce the composite kidney outcome</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i in people with diabetes for reno-protection</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">DPP-4i</td></tr>
<tr><td rowspan="1" colspan="1">Recommended for people with diabetes for reno-protection</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACEi or ARB</td></tr>
<tr><td rowspan="1" colspan="1">First-line treatment agents for people with diabetes and hypertension</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">ARB in combination with CCBs or diuretics in people with DM, to reduce the risk of CVDs and renal disorders</td></tr>
<tr><td rowspan="1" colspan="1">ARB monotherapy or combination therapy with CCBs in people with DM to control BP</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Both ARB and ACEi in people with diabetes and hypertension, to reduce the risk of ESKD</td></tr>
<tr><td rowspan="1" colspan="1">ACEi/ARB alone or in combination with SGLT-2i in people with T2D for controlling BP and eGFR</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Diuretics</td></tr>
<tr><td rowspan="1" colspan="1">Thiazides alongside ACEi or ARBs in people with DM for the management of hypertension</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Thiazides and beta blockers are not recommended in people with diabetes and hypertension, as they cause CV events and hyperglycemia</td></tr>
<tr><td rowspan="1" colspan="1">Thiazide in eGFR of ≥40 mL/minute/1.73 m<sup>2</sup>
</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Loop diuretics in eGFR of ≤40-50 mL/minute/1.73 m<sup>2</sup>
</td></tr>
<tr>
<td rowspan="8" colspan="1">[<a href="#REF116" class="usa-link" aria-describedby="REF116">116</a>]</td>
<td rowspan="8" colspan="1">Indian Society of Hypertension guideline (2023)</td>
<td rowspan="1" colspan="1">SGLT-2i and GLP-1RA</td>
</tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">SGLT-2i in people with T2D to reduce CVD/CKD risk and HF and in diabetic/nondiabetic nephropathies when eGFR is 20 or 25 mL/minute/1.73<sup>2</sup>
</td></tr>
<tr><td rowspan="1" colspan="1">SGLT-2i or GLP-1RA in obese people with diabetes and hypertension, to reduce body weight and BP</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">Statin therapy</td></tr>
<tr><td rowspan="1" colspan="1">Statins in people with hypertension and dyslipidemia to prevent CVDs</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACEi or ARB</td></tr>
<tr><td rowspan="1" colspan="1">ACEi and ARB in people with proteinuria or microalbuminuria</td></tr>
<tr style="background-color:#ccc"><td rowspan="1" colspan="1">ACEi or ARB (or beta blockers) in people with hypertension and CAD</td></tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/TAB1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec3"><h2 class="pmc_sec_title">Conclusions</h2>
<p>Modifiable risk factors, including diabetes, dyslipidemia, and hypertension, increase inflammatory markers and ADMA, decrease nitric oxide bioavailability, and result in endothelial dysfunction. This in turn causes hypertension or albuminuria, leading to atherosclerosis-mediated CV or kidney damage/failure. The timely diagnosis and management of the vascular complications at “prevent” and “regress” stages of the diabetes-kidney-heart continuum are crucial for delaying the irreparable consequences of the “retard” stage. Moreover, individual risk stratification must be prioritized during the selection of first-line therapy and transition to other suitable therapies to delay the continuum. Metformin and SGLT-2i are the first-line treatment for patients with T2D and CKD (if eGFR allows). In case the HbA1c goal is not achieved with the first-line therapies, GLP-1RA can be used in people with diabetes but without congestive HF.</p>
<p>Secondary prevention with SGLT-2i or GLP-1RA in people with T2D, CVD, and CKD (eGFR of ≥20 mL/minute/1.73 m<sup>2</sup>) can be considered for reducing both CV risk and albuminuria. Dipeptidyl peptidase-4 inhibitors provide reno-protection by potentially reducing UACR and a decline in eGFR. Monotherapy of ACEi or ARB or a combination therapy with SGLT-2i is recommended in people with T2D for controlling BP and eGFR. The use of RAS blockers reduces the risk of hHF or death in people with T2D and CVD (including HF) or CKD (including moderate-to-severely increased albuminuria). Similarly, MRAs reduce the risk of hHF and death in T2D patients having HF with reduced EF. Lipid lowering with statin therapy is recommended in people with diabetes and established CVD. In advanced CKD patients, the use of fibrate, omega-3 supplementation, bile acid sequestrants, and PCKS9 inhibitor has shown promising effects in reducing triglyceride, LDL-C, MACE, and CV death. In addition to the systematic approach, improving treatment adherence is equally important, with a focus on minimizing prescription costs, active monitoring, and providing health literacy to obtain greater treatment outcome.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>Alembic Pharmaceuticals Ltd. provided funds for medical writing support. The authors thank WorkSure® India for providing the medical writing and editing assistance for this manuscript.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Disclosures</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Conflicts of interest:</strong> In compliance with the ICMJE uniform disclosure form, all authors declare the following:</p>
<p><strong>Payment/services info:</strong> All authors have declared that no financial support was received from any organization for the submitted work.</p>
<p><strong>Financial relationships:</strong> Sanjay Jain and Onkar Swami declare(s) employment from Alembic Pharmaceuticals Ltd. Both authors are full-time employees of Alembic Pharmaceuticals Ltd.</p>
<p><strong>Other relationships:</strong> All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</p>
</div></div></section><section id="fn-group2" class="fn-group"><h2 class="pmc_sec_title">Author Contributions</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn2">
<p><strong>Concept and design:</strong>  Onkar C. Swami, Abdul Hamid Zargar, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Alan Almeida, Abhijit Taraphder, Sandeep Bansal, Sameer Dani, Nilakshi Deka, Sanjay Jain</p>
<p><strong>Acquisition, analysis, or interpretation of data:</strong>  Onkar C. Swami, Abdul Hamid Zargar, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Alan Almeida, Abhijit Taraphder, Sandeep Bansal, Sameer Dani, Nilakshi Deka, Sanjay Jain</p>
<p><strong>Drafting of the manuscript:</strong>  Onkar C. Swami, Abdul Hamid Zargar, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Alan Almeida, Abhijit Taraphder, Sandeep Bansal, Sameer Dani, Nilakshi Deka, Sanjay Jain</p>
<p><strong>Critical review of the manuscript for important intellectual content:</strong>  Onkar C. Swami, Abdul Hamid Zargar, Jayagopal Pathiyil Balagopalan, Arpandev Bhattacharyya, Alan Almeida, Abhijit Taraphder, Sandeep Bansal, Sameer Dani, Nilakshi Deka, Sanjay Jain</p>
</div></div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="REF1">
<span class="label">1.</span><cite>Sodium-glucose cotransporter-2 inhibitors and cardiovascular protection among patients with type 2 diabetes mellitus: a systematic review. Yankah RK, Anku EK, Eligar V. J Diabetes Res. 2024;2024:9985836. doi: 10.1155/2024/9985836.</cite> [<a href="https://doi.org/10.1155/2024/9985836" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11102109/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38766320/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Res&amp;title=Sodium-glucose%20cotransporter-2%20inhibitors%20and%20cardiovascular%20protection%20among%20patients%20with%20type%202%20diabetes%20mellitus:%20a%20systematic%20review&amp;volume=2024&amp;publication_year=2024&amp;pages=9985836&amp;pmid=38766320&amp;doi=10.1155/2024/9985836&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF2">
<span class="label">2.</span><cite>Diabetes and global ageing among 65-99-year-old adults: findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, Williams R. Diabetes Res Clin Pract. 2020;162:108078. doi: 10.1016/j.diabres.2020.108078.</cite> [<a href="https://doi.org/10.1016/j.diabres.2020.108078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32068097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Res%20Clin%20Pract&amp;title=Diabetes%20and%20global%20ageing%20among%2065-99-year-old%20adults:%20findings%20from%20the%20International%20Diabetes%20Federation%20Diabetes%20Atlas,%209(th)%20edition&amp;volume=162&amp;publication_year=2020&amp;pages=108078&amp;pmid=32068097&amp;doi=10.1016/j.diabres.2020.108078&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF3">
<span class="label">3.</span><cite>Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Petrie JR, Guzik TJ, Touyz RM. Can J Cardiol. 2018;34:575–584. doi: 10.1016/j.cjca.2017.12.005.</cite> [<a href="https://doi.org/10.1016/j.cjca.2017.12.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5953551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29459239/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Cardiol&amp;title=Diabetes,%20hypertension,%20and%20cardiovascular%20disease:%20clinical%20insights%20and%20vascular%20mechanisms&amp;volume=34&amp;publication_year=2018&amp;pages=575-584&amp;pmid=29459239&amp;doi=10.1016/j.cjca.2017.12.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF4">
<span class="label">4.</span><cite>The significance of chronic kidney disease, heart failure and cardiovascular disease for mortality in type 1 diabetes: nationwide observational study. Eliasson B, Lyngfelt L, Strömblad SO, Franzén S, Eeg-Olofsson K. Sci Rep. 2022;12:17950. doi: 10.1038/s41598-022-22932-4.</cite> [<a href="https://doi.org/10.1038/s41598-022-22932-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9606313/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36289275/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=The%20significance%20of%20chronic%20kidney%20disease,%20heart%20failure%20and%20cardiovascular%20disease%20for%20mortality%20in%20type%201%20diabetes:%20nationwide%20observational%20study&amp;volume=12&amp;publication_year=2022&amp;pages=17950&amp;pmid=36289275&amp;doi=10.1038/s41598-022-22932-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF5">
<span class="label">5.</span><cite>Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes. Cabrera CS, Lee AS, Olsson M, et al.  Kidney Int Rep. 2020;5:1651–1660. doi: 10.1016/j.ekir.2020.07.029.</cite> [<a href="https://doi.org/10.1016/j.ekir.2020.07.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7569691/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33102957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int%20Rep&amp;title=Impact%20of%20CKD%20progression%20on%20cardiovascular%20disease%20risk%20in%20a%20contemporary%20UK%20cohort%20of%20individuals%20with%20diabetes&amp;volume=5&amp;publication_year=2020&amp;pages=1651-1660&amp;pmid=33102957&amp;doi=10.1016/j.ekir.2020.07.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF6">
<span class="label">6.</span><cite>eGFR slope as predictor of mortality in heart failure patients. Verstreken S, Beles M, Oeste CL, et al.  ESC Heart Fail. 2025;12:1217–1226. doi: 10.1002/ehf2.15128.</cite> [<a href="https://doi.org/10.1002/ehf2.15128" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11911612/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39601340/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESC%20Heart%20Fail&amp;title=eGFR%20slope%20as%20predictor%20of%20mortality%20in%20heart%20failure%20patients&amp;volume=12&amp;publication_year=2025&amp;pages=1217-1226&amp;pmid=39601340&amp;doi=10.1002/ehf2.15128&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF7">
<span class="label">7.</span><cite>Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes. Bell DS, McGill JB, Jerkins T. Diabetes Obes Metab. 2023;25:2795–2804. doi: 10.1111/dom.15181.</cite> [<a href="https://doi.org/10.1111/dom.15181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37409564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Management%20of%20the%20'wicked'%20combination%20of%20heart%20failure%20and%20chronic%20kidney%20disease%20in%20the%20patient%20with%20diabetes&amp;volume=25&amp;publication_year=2023&amp;pages=2795-2804&amp;pmid=37409564&amp;doi=10.1111/dom.15181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF8">
<span class="label">8.</span><cite>Prevalence of cardiovascular and renal co-morbidities in patients with type 2 diabetes in the Gulf, a cross-sectional observational study. Al-Ozairi E, Jallo MK, Hafidh K, et al.  Diabetes Ther. 2021;12:1193–1207. doi: 10.1007/s13300-021-01038-6.</cite> [<a href="https://doi.org/10.1007/s13300-021-01038-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7994503/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33694092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Ther&amp;title=Prevalence%20of%20cardiovascular%20and%20renal%20co-morbidities%20in%20patients%20with%20type%202%20diabetes%20in%20the%20Gulf,%20a%20cross-sectional%20observational%20study&amp;volume=12&amp;publication_year=2021&amp;pages=1193-1207&amp;pmid=33694092&amp;doi=10.1007/s13300-021-01038-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF9">
<span class="label">9.</span><cite>Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Ndumele CE, Rangaswami J, Chow SL, et al.  Circulation. 2023;148:1606–1635. doi: 10.1161/CIR.0000000000001184.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000001184" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37807924/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Cardiovascular-kidney-metabolic%20health:%20a%20presidential%20advisory%20from%20the%20American%20Heart%20Association&amp;volume=148&amp;publication_year=2023&amp;pages=1606-1635&amp;pmid=37807924&amp;doi=10.1161/CIR.0000000000001184&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF10">
<span class="label">10.</span><cite>Amsterdam, Netherlands: International Diabetes Federation; 2025. IDF Diabetes Atlas 11th Edition.</cite> [<a href="https://scholar.google.com/scholar_lookup?Amsterdam,%20Netherlands:%20International%20Diabetes%20Federation;%202025.%20IDF%20Diabetes%20Atlas%2011th%20Edition." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF11">
<span class="label">11.</span><cite>Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Einarson TR, Acs A, Ludwig C, Panton UH. Cardiovasc Diabetol. 2018;17:83. doi: 10.1186/s12933-018-0728-6.</cite> [<a href="https://doi.org/10.1186/s12933-018-0728-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5994068/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29884191/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Prevalence%20of%20cardiovascular%20disease%20in%20type%202%20diabetes:%20a%20systematic%20literature%20review%20of%20scientific%20evidence%20from%20across%20the%20world%20in%202007-2017&amp;volume=17&amp;publication_year=2018&amp;pages=83&amp;pmid=29884191&amp;doi=10.1186/s12933-018-0728-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF12">
<span class="label">12.</span><cite>Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Iglay K, Hannachi H, Joseph Howie P, et al.  Curr Med Res Opin. 2016;32:1243–1252. doi: 10.1185/03007995.2016.1168291.</cite> [<a href="https://doi.org/10.1185/03007995.2016.1168291" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26986190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Med%20Res%20Opin&amp;title=Prevalence%20and%20co-prevalence%20of%20comorbidities%20among%20patients%20with%20type%202%20diabetes%20mellitus&amp;volume=32&amp;publication_year=2016&amp;pages=1243-1252&amp;pmid=26986190&amp;doi=10.1185/03007995.2016.1168291&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF13">
<span class="label">13.</span><cite>Indian guidance on cardiovascular and renal comorbidity management in type-2 diabetes mellitus. Das AK, Unnikrishnan AG, Saboo B, Mohan V, Vijay V. J Assoc Physicians India. 2018;7</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Assoc%20Physicians%20India&amp;title=Indian%20guidance%20on%20cardiovascular%20and%20renal%20comorbidity%20management%20in%20type-2%20diabetes%20mellitus&amp;volume=7&amp;publication_year=2018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF14">
<span class="label">14.</span><cite>Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. Anand S, Shivashankar R, Ali MK, et al.  Kidney Int. 2015;88:178–185. doi: 10.1038/ki.2015.58.</cite> [<a href="https://doi.org/10.1038/ki.2015.58" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4490055/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25786102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Prevalence%20of%20chronic%20kidney%20disease%20in%20two%20major%20Indian%20cities%20and%20projections%20for%20associated%20cardiovascular%20disease&amp;volume=88&amp;publication_year=2015&amp;pages=178-185&amp;pmid=25786102&amp;doi=10.1038/ki.2015.58&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF15">
<span class="label">15.</span><cite>Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes. Wang Y, Katzmarzyk PT, Horswell R, Zhao W, Johnson J, Hu G. Kidney Int. 2014;85:1192–1199. doi: 10.1038/ki.2013.396.</cite> [<a href="https://doi.org/10.1038/ki.2013.396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4141539/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24107845/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Kidney%20function%20and%20the%20risk%20of%20cardiovascular%20disease%20in%20patients%20with%20type%202%20diabetes&amp;volume=85&amp;publication_year=2014&amp;pages=1192-1199&amp;pmid=24107845&amp;doi=10.1038/ki.2013.396&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF16">
<span class="label">16.</span><cite>Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. Zhang R, Mamza JB, Morris T, et al.  BMC Med. 2022;20:63. doi: 10.1186/s12916-022-02234-2.</cite> [<a href="https://doi.org/10.1186/s12916-022-02234-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8822817/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35130878/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Med&amp;title=Lifetime%20risk%20of%20cardiovascular-renal%20disease%20in%20type%202%20diabetes:%20a%20population-based%20study%20in%20473,399%20individuals&amp;volume=20&amp;publication_year=2022&amp;pages=63&amp;pmid=35130878&amp;doi=10.1186/s12916-022-02234-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF17">
<span class="label">17.</span><cite>Cardiovascular and renal outcomes with sodium glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus: a system review and network meta-analysis. Tian L, Ai S, Zheng H, et al.  Front Pharmacol. 2022;13:986186. doi: 10.3389/fphar.2022.986186.</cite> [<a href="https://doi.org/10.3389/fphar.2022.986186" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9731650/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36506550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Cardiovascular%20and%20renal%20outcomes%20with%20sodium%20glucose%20co-transporter%202%20inhibitors%20in%20patients%20with%20type%202%20diabetes%20mellitus:%20a%20system%20review%20and%20network%20meta-analysis&amp;volume=13&amp;publication_year=2022&amp;pages=986186&amp;pmid=36506550&amp;doi=10.3389/fphar.2022.986186&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF18">
<span class="label">18.</span><cite>Liraglutide and renal outcomes in type 2 diabetes. Mann JF, Ørsted DD, Brown-Frandsen K, et al.  N Engl J Med. 2017;377:839–848. doi: 10.1056/NEJMoa1616011.</cite> [<a href="https://doi.org/10.1056/NEJMoa1616011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28854085/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Liraglutide%20and%20renal%20outcomes%20in%20type%202%20diabetes&amp;volume=377&amp;publication_year=2017&amp;pages=839-848&amp;pmid=28854085&amp;doi=10.1056/NEJMoa1616011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF19">
<span class="label">19.</span><cite>Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. Gerstein HC, Sattar N, Rosenstock J, et al.  N Engl J Med. 2021;385:896–907. doi: 10.1056/NEJMoa2108269.</cite> [<a href="https://doi.org/10.1056/NEJMoa2108269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34215025/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cardiovascular%20and%20renal%20outcomes%20with%20efpeglenatide%20in%20type%202%20diabetes&amp;volume=385&amp;publication_year=2021&amp;pages=896-907&amp;pmid=34215025&amp;doi=10.1056/NEJMoa2108269&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF20">
<span class="label">20.</span><cite>Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. Zinman B, Wanner C, Lachin JM, et al.  N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720.</cite> [<a href="https://doi.org/10.1056/NEJMoa1504720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26378978/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Empagliflozin,%20cardiovascular%20outcomes,%20and%20mortality%20in%20type%202%20diabetes&amp;volume=373&amp;publication_year=2015&amp;pages=2117-2128&amp;pmid=26378978&amp;doi=10.1056/NEJMoa1504720&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF21">
<span class="label">21.</span><cite>Vascular calcification in chronic kidney disease: an update. Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Nephrol Dial Transplant. 2016;31:31–39. doi: 10.1093/ndt/gfv111.</cite> [<a href="https://doi.org/10.1093/ndt/gfv111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25916871/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nephrol%20Dial%20Transplant&amp;title=Vascular%20calcification%20in%20chronic%20kidney%20disease:%20an%20update&amp;volume=31&amp;publication_year=2016&amp;pages=31-39&amp;pmid=25916871&amp;doi=10.1093/ndt/gfv111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF22">
<span class="label">22.</span><cite>[The cardiorenal continuum: a proposal for the prevention of cardiovascular and renal diseases] (Article in Spanish) Maimi PA, Rodulfo IA. Rev Colomb Nefrol. 2020;7:60–69.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Rev%20Colomb%20Nefrol&amp;title=%5BThe%20cardiorenal%20continuum:%20a%20proposal%20for%20the%20prevention%20of%20cardiovascular%20and%20renal%20diseases%5D%20(Article%20in%20Spanish)&amp;volume=7&amp;publication_year=2020&amp;pages=60-69&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF23">
<span class="label">23.</span><cite>Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches. Düsing P, Zietzer A, Goody PR, Hosen MR, Kurts C, Nickenig G, Jansen F. J Mol Med (Berl) 2021;99:335–348. doi: 10.1007/s00109-021-02037-7.</cite> [<a href="https://doi.org/10.1007/s00109-021-02037-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7900031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33481059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Mol%20Med%20(Berl)&amp;title=Vascular%20pathologies%20in%20chronic%20kidney%20disease:%20pathophysiological%20mechanisms%20and%20novel%20therapeutic%20approaches&amp;volume=99&amp;publication_year=2021&amp;pages=335-348&amp;pmid=33481059&amp;doi=10.1007/s00109-021-02037-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF24">
<span class="label">24.</span><cite>Outcomes of asymptomatic left ventricular dysfunction in the patient with or without type 2 diabetic mellitus. Ling L, Sung SH. Eur Heart J. 2023;44:655–835.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Outcomes%20of%20asymptomatic%20left%20ventricular%20dysfunction%20in%20the%20patient%20with%20or%20without%20type%202%20diabetic%20mellitus&amp;volume=44&amp;publication_year=2023&amp;pages=655-835&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF25">
<span class="label">25.</span><cite>Diagnosis of cardiovascular disease in patients with chronic kidney disease. Zoccali C, Mark PB, Sarafidis P, et al.  Nat Rev Nephrol. 2023;19:733–746. doi: 10.1038/s41581-023-00747-4.</cite> [<a href="https://doi.org/10.1038/s41581-023-00747-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37612381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Nephrol&amp;title=Diagnosis%20of%20cardiovascular%20disease%20in%20patients%20with%20chronic%20kidney%20disease&amp;volume=19&amp;publication_year=2023&amp;pages=733-746&amp;pmid=37612381&amp;doi=10.1038/s41581-023-00747-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF26">
<span class="label">26.</span><cite>Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Pop-Busui R, Januzzi JL, Bruemmer D, et al.  Diabetes Care. 2022;45:1670–1690. doi: 10.2337/dci22-0014.</cite> [<a href="https://doi.org/10.2337/dci22-0014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9726978/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35796765/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Heart%20failure:%20an%20underappreciated%20complication%20of%20diabetes.%20A%20consensus%20report%20of%20the%20American%20Diabetes%20Association&amp;volume=45&amp;publication_year=2022&amp;pages=1670-1690&amp;pmid=35796765&amp;doi=10.2337/dci22-0014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF27">
<span class="label">27.</span><cite>Higher BNP/NT-pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta-analysis. Hendricks S, Dykun I, Balcer B, Totzeck M, Rassaf T, Mahabadi AA. ESC Heart Fail. 2022;9:3198–3209. doi: 10.1002/ehf2.14019.</cite> [<a href="https://doi.org/10.1002/ehf2.14019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9715818/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35769032/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=ESC%20Heart%20Fail&amp;title=Higher%20BNP/NT-pro%20BNP%20levels%20stratify%20prognosis%20equally%20well%20in%20patients%20with%20and%20without%20heart%20failure:%20a%20meta-analysis&amp;volume=9&amp;publication_year=2022&amp;pages=3198-3209&amp;pmid=35769032&amp;doi=10.1002/ehf2.14019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF28">
<span class="label">28.</span><cite>Cardiac troponins for the diagnosis of acute myocardial infarction in chronic kidney disease. Kraus D, von Jeinsen B, Tzikas S, et al.  J Am Heart Assoc. 2018;7:0. doi: 10.1161/JAHA.117.008032.</cite> [<a href="https://doi.org/10.1161/JAHA.117.008032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6404905/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30371308/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&amp;title=Cardiac%20troponins%20for%20the%20diagnosis%20of%20acute%20myocardial%20infarction%20in%20chronic%20kidney%20disease&amp;volume=7&amp;publication_year=2018&amp;pages=0&amp;pmid=30371308&amp;doi=10.1161/JAHA.117.008032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF29">
<span class="label">29.</span><cite>Biomarkers for the diagnosis of heart failure in people with diabetes: a consensus report from Diabetes Technology Society. Yeung AM, Huang J, Pandey A, et al.  Prog Cardiovasc Dis. 2023;79:65–79. doi: 10.1016/j.pcad.2023.05.002.</cite> [<a href="https://doi.org/10.1016/j.pcad.2023.05.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37178991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Prog%20Cardiovasc%20Dis&amp;title=Biomarkers%20for%20the%20diagnosis%20of%20heart%20failure%20in%20people%20with%20diabetes:%20a%20consensus%20report%20from%20Diabetes%20Technology%20Society&amp;volume=79&amp;publication_year=2023&amp;pages=65-79&amp;pmid=37178991&amp;doi=10.1016/j.pcad.2023.05.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF30">
<span class="label">30.</span><cite>Automated interpretation of systolic and diastolic function on the echocardiogram: a multicohort study. Tromp J, Seekings PJ, Hung CL, et al.  Lancet Digit Health. 2022;4:0–54. doi: 10.1016/S2589-7500(21)00235-1.</cite> [<a href="https://doi.org/10.1016/S2589-7500(21)00235-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34863649/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Digit%20Health&amp;title=Automated%20interpretation%20of%20systolic%20and%20diastolic%20function%20on%20the%20echocardiogram:%20a%20multicohort%20study&amp;volume=4&amp;publication_year=2022&amp;pages=0-54&amp;pmid=34863649&amp;doi=10.1016/S2589-7500(21)00235-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF31">
<span class="label">31.</span><cite>Deep learning interpretation of echocardiograms. Ghorbani A, Ouyang D, Abid A, et al.  NPJ Digit Med. 2020;3:10. doi: 10.1038/s41746-019-0216-8.</cite> [<a href="https://doi.org/10.1038/s41746-019-0216-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6981156/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31993508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=NPJ%20Digit%20Med&amp;title=Deep%20learning%20interpretation%20of%20echocardiograms&amp;volume=3&amp;publication_year=2020&amp;pages=10&amp;pmid=31993508&amp;doi=10.1038/s41746-019-0216-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF32">
<span class="label">32.</span><cite>Association between MR-proADM concentration and treatment intensity of antihypertensive agents in chronic kidney disease patients with insufficient blood pressure control. Iwao M, Tanaka R, Suzuki Y, et al.  Sci Rep. 2021;11:21931. doi: 10.1038/s41598-021-01403-2.</cite> [<a href="https://doi.org/10.1038/s41598-021-01403-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8578546/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34754024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Association%20between%20MR-proADM%20concentration%20and%20treatment%20intensity%20of%20antihypertensive%20agents%20in%20chronic%20kidney%20disease%20patients%20with%20insufficient%20blood%20pressure%20control&amp;volume=11&amp;publication_year=2021&amp;pages=21931&amp;pmid=34754024&amp;doi=10.1038/s41598-021-01403-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF33">
<span class="label">33.</span><cite>Chronic kidney disease diagnosis and management: a review. Chen TK, Knicely DH, Grams ME. JAMA. 2019;322:1294–1304. doi: 10.1001/jama.2019.14745.</cite> [<a href="https://doi.org/10.1001/jama.2019.14745" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7015670/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31573641/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Chronic%20kidney%20disease%20diagnosis%20and%20management:%20a%20review&amp;volume=322&amp;publication_year=2019&amp;pages=1294-1304&amp;pmid=31573641&amp;doi=10.1001/jama.2019.14745&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF34">
<span class="label">34.</span><cite>The utility of estimation of glomerular filtration rate by serum cystatin C as a predictor of diabetic kidney disease in both type I and type II diabetic patients: a single center study. Mansour AE, Abdelmoniem RO, Elbadawy AM, Ibrahim WM. Egypt J Intern Med. 2023;35:64.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Egypt%20J%20Intern%20Med&amp;title=The%20utility%20of%20estimation%20of%20glomerular%20filtration%20rate%20by%20serum%20cystatin%20C%20as%20a%20predictor%20of%20diabetic%20kidney%20disease%20in%20both%20type%20I%20and%20type%20II%20diabetic%20patients:%20a%20single%20center%20study&amp;volume=35&amp;publication_year=2023&amp;pages=64&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF35">
<span class="label">35.</span><cite>Liquid biopsy: a new avenue for the diagnosis of kidney disease: diabetic kidney disease, renal cancer, and IgA nephropathy. Dybiec J, Frąk W, Kućmierz J, et al.  Genes (Basel) 2024;15:78. doi: 10.3390/genes15010078.</cite> [<a href="https://doi.org/10.3390/genes15010078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10815875/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38254967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Genes%20(Basel)&amp;title=Liquid%20biopsy:%20a%20new%20avenue%20for%20the%20diagnosis%20of%20kidney%20disease:%20diabetic%20kidney%20disease,%20renal%20cancer,%20and%20IgA%20nephropathy&amp;volume=15&amp;publication_year=2024&amp;pages=78&amp;pmid=38254967&amp;doi=10.3390/genes15010078&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF36">
<span class="label">36.</span><cite>A new era in diabetic kidney disease treatment: the four pillars and strategies to build beyond. Han S, Kim S. Electrolyte Blood Press. 2024;22:21–28. doi: 10.5049/EBP.2024.22.2.21.</cite> [<a href="https://doi.org/10.5049/EBP.2024.22.2.21" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11704317/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39780853/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Electrolyte%20Blood%20Press&amp;title=A%20new%20era%20in%20diabetic%20kidney%20disease%20treatment:%20the%20four%20pillars%20and%20strategies%20to%20build%20beyond&amp;volume=22&amp;publication_year=2024&amp;pages=21-28&amp;pmid=39780853&amp;doi=10.5049/EBP.2024.22.2.21&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF37">
<span class="label">37.</span><cite>KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2022;102:0. doi: 10.1016/j.kint.2022.06.008.</cite> [<a href="https://doi.org/10.1016/j.kint.2022.06.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36272764/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=KDIGO%202022%20clinical%20practice%20guideline%20for%20diabetes%20management%20in%20chronic%20kidney%20disease&amp;volume=102&amp;publication_year=2022&amp;pages=0&amp;pmid=36272764&amp;doi=10.1016/j.kint.2022.06.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF38">
<span class="label">38.</span><cite>KDIGO 2024 clinical practice Guideline for the evaluation and management of chronic kidney disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int. 2024;105:0–314. doi: 10.1016/j.kint.2023.10.018.</cite> [<a href="https://doi.org/10.1016/j.kint.2023.10.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38490803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=KDIGO%202024%20clinical%20practice%20Guideline%20for%20the%20evaluation%20and%20management%20of%20chronic%20kidney%20disease&amp;volume=105&amp;publication_year=2024&amp;pages=0-314&amp;pmid=38490803&amp;doi=10.1016/j.kint.2023.10.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF39">
<span class="label">39.</span><cite>Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. McGuire DK, Shih WJ, Cosentino F, et al.  JAMA Cardiol. 2021;6:148–158. doi: 10.1001/jamacardio.2020.4511.</cite> [<a href="https://doi.org/10.1001/jamacardio.2020.4511" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7542529/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33031522/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Cardiol&amp;title=Association%20of%20SGLT2%20inhibitors%20with%20cardiovascular%20and%20kidney%20outcomes%20in%20patients%20with%20type%202%20diabetes:%20a%20meta-analysis&amp;volume=6&amp;publication_year=2021&amp;pages=148-158&amp;pmid=33031522&amp;doi=10.1001/jamacardio.2020.4511&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF40">
<span class="label">40.</span><cite>Sotagliflozin in patients with diabetes and chronic kidney disease. Bhatt DL, Szarek M, Pitt B, et al.  N Engl J Med. 2021;384:129–139. doi: 10.1056/NEJMoa2030186.</cite> [<a href="https://doi.org/10.1056/NEJMoa2030186" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33200891/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Sotagliflozin%20in%20patients%20with%20diabetes%20and%20chronic%20kidney%20disease&amp;volume=384&amp;publication_year=2021&amp;pages=129-139&amp;pmid=33200891&amp;doi=10.1056/NEJMoa2030186&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF41">
<span class="label">41.</span><cite>Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. Zelniker TA, Braunwald E. J Am Coll Cardiol. 2020;75:435–447. doi: 10.1016/j.jacc.2019.11.036.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.11.036" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32000956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Clinical%20benefit%20of%20cardiorenal%20effects%20of%20sodium-glucose%20cotransporter%202%20inhibitors:%20JACC%20state-of-the-art%20review&amp;volume=75&amp;publication_year=2020&amp;pages=435-447&amp;pmid=32000956&amp;doi=10.1016/j.jacc.2019.11.036&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF42">
<span class="label">42.</span><cite>Effects of dapagliflozin in patients with kidney disease, with and without heart failure. McMurray JJ, Wheeler DC, Stefánsson BV, et al.  JACC Heart Fail. 2021;9:807–820. doi: 10.1016/j.jchf.2021.06.017.</cite> [<a href="https://doi.org/10.1016/j.jchf.2021.06.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34446370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JACC%20Heart%20Fail&amp;title=Effects%20of%20dapagliflozin%20in%20patients%20with%20kidney%20disease,%20with%20and%20without%20heart%20failure&amp;volume=9&amp;publication_year=2021&amp;pages=807-820&amp;pmid=34446370&amp;doi=10.1016/j.jchf.2021.06.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF43">
<span class="label">43.</span><cite>Dapagliflozin in patients with heart failure and reduced ejection fraction. McMurray JJ, Solomon SD, Inzucchi SE, et al.  N Engl J Med. 2019;381:1995–2008. doi: 10.1056/NEJMoa1911303.</cite> [<a href="https://doi.org/10.1056/NEJMoa1911303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31535829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Dapagliflozin%20in%20patients%20with%20heart%20failure%20and%20reduced%20ejection%20fraction&amp;volume=381&amp;publication_year=2019&amp;pages=1995-2008&amp;pmid=31535829&amp;doi=10.1056/NEJMoa1911303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF44">
<span class="label">44.</span><cite>Cardiovascular and renal outcomes with empagliflozin in heart failure. Packer M, Anker SD, Butler J, et al.  N Engl J Med. 2020;383:1413–1424. doi: 10.1056/NEJMoa2022190.</cite> [<a href="https://doi.org/10.1056/NEJMoa2022190" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32865377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cardiovascular%20and%20renal%20outcomes%20with%20empagliflozin%20in%20heart%20failure&amp;volume=383&amp;publication_year=2020&amp;pages=1413-1424&amp;pmid=32865377&amp;doi=10.1056/NEJMoa2022190&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF45">
<span class="label">45.</span><cite>Sotagliflozin in patients with diabetes and recent worsening heart failure. Bhatt DL, Szarek M, Steg PG, et al.  N Engl J Med. 2021;384:117–128. doi: 10.1056/NEJMoa2030183.</cite> [<a href="https://doi.org/10.1056/NEJMoa2030183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33200892/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Sotagliflozin%20in%20patients%20with%20diabetes%20and%20recent%20worsening%20heart%20failure&amp;volume=384&amp;publication_year=2021&amp;pages=117-128&amp;pmid=33200892&amp;doi=10.1056/NEJMoa2030183&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF46">
<span class="label">46.</span><cite>Management of diabetes mellitus in patients with CKD: core curriculum 2022. Hahr AJ, Molitch ME. Am J Kidney Dis. 2022;79:728–736. doi: 10.1053/j.ajkd.2021.05.023.</cite> [<a href="https://doi.org/10.1053/j.ajkd.2021.05.023" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34600745/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Kidney%20Dis&amp;title=Management%20of%20diabetes%20mellitus%20in%20patients%20with%20CKD:%20core%20curriculum%202022&amp;volume=79&amp;publication_year=2022&amp;pages=728-736&amp;pmid=34600745&amp;doi=10.1053/j.ajkd.2021.05.023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF47">
<span class="label">47.</span><cite>Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: a systemic review and meta-analysis. Mima A, Gotoda H, Lee R, Murakami A, Akai R, Lee S. Metabol Open. 2023;17:100236. doi: 10.1016/j.metop.2023.100236.</cite> [<a href="https://doi.org/10.1016/j.metop.2023.100236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10009293/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36923991/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Metabol%20Open&amp;title=Effects%20of%20incretin-based%20therapeutic%20agents%20including%20tirzepatide%20on%20renal%20outcomes%20in%20patients%20with%20type%202%20diabetes:%20a%20systemic%20review%20and%20meta-analysis&amp;volume=17&amp;publication_year=2023&amp;pages=100236&amp;pmid=36923991&amp;doi=10.1016/j.metop.2023.100236&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF48">
<span class="label">48.</span><cite>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Kristensen SL, Rørth R, Jhund PS, et al.  Lancet Diabetes Endocrinol. 2019;7:776–785. doi: 10.1016/S2213-8587(19)30249-9.</cite> [<a href="https://doi.org/10.1016/S2213-8587(19)30249-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31422062/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&amp;title=Cardiovascular,%20mortality,%20and%20kidney%20outcomes%20with%20GLP-1%20receptor%20agonists%20in%20patients%20with%20type%202%20diabetes:%20a%20systematic%20review%20and%20meta-analysis%20of%20cardiovascular%20outcome%20trials&amp;volume=7&amp;publication_year=2019&amp;pages=776-785&amp;pmid=31422062&amp;doi=10.1016/S2213-8587(19)30249-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF49">
<span class="label">49.</span><cite>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Sattar N, Lee MM, Kristensen SL, et al.  Lancet Diabetes Endocrinol. 2021;9:653–662. doi: 10.1016/S2213-8587(21)00203-5.</cite> [<a href="https://doi.org/10.1016/S2213-8587(21)00203-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34425083/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&amp;title=Cardiovascular,%20mortality,%20and%20kidney%20outcomes%20with%20GLP-1%20receptor%20agonists%20in%20patients%20with%20type%202%20diabetes:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomised%20trials&amp;volume=9&amp;publication_year=2021&amp;pages=653-662&amp;pmid=34425083&amp;doi=10.1016/S2213-8587(21)00203-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF50">
<span class="label">50.</span><cite>Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis. Rossing P, Bain SC, Bosch-Traberg H, Sokareva E, Heerspink HJ, Rasmussen S, Mellbin LG. Cardiovasc Diabetol. 2023;22:220. doi: 10.1186/s12933-023-01949-7.</cite> [<a href="https://doi.org/10.1186/s12933-023-01949-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10463803/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37620807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Effect%20of%20semaglutide%20on%20major%20adverse%20cardiovascular%20events%20by%20baseline%20kidney%20parameters%20in%20participants%20with%20type%202%20diabetes%20and%20at%20high%20risk%20of%20cardiovascular%20disease:%20SUSTAIN%206%20and%20PIONEER%206%20post%20hoc%20pooled%20analysis&amp;volume=22&amp;publication_year=2023&amp;pages=220&amp;pmid=37620807&amp;doi=10.1186/s12933-023-01949-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF51">
<span class="label">51.</span><cite>Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Muskiet MH, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJ, van Raalte DH. Lancet Diabetes Endocrinol. 2018;6:859–869. doi: 10.1016/S2213-8587(18)30268-7.</cite> [<a href="https://doi.org/10.1016/S2213-8587(18)30268-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30292589/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&amp;title=Lixisenatide%20and%20renal%20outcomes%20in%20patients%20with%20type%202%20diabetes%20and%20acute%20coronary%20syndrome:%20an%20exploratory%20analysis%20of%20the%20ELIXA%20randomised,%20placebo-controlled%20trial&amp;volume=6&amp;publication_year=2018&amp;pages=859-869&amp;pmid=30292589&amp;doi=10.1016/S2213-8587(18)30268-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF52">
<span class="label">52.</span><cite>Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases. Bashier A, Bin Hussain A, Abdelgadir E, Alawadi F, Sabbour H, Chilton R. Diabetol Metab Syndr. 2019;11:80. doi: 10.1186/s13098-019-0476-0.</cite> [<a href="https://doi.org/10.1186/s13098-019-0476-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6761728/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31572499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetol%20Metab%20Syndr&amp;title=Consensus%20recommendations%20for%20management%20of%20patients%20with%20type%202%20diabetes%20mellitus%20and%20cardiovascular%20diseases&amp;volume=11&amp;publication_year=2019&amp;pages=80&amp;pmid=31572499&amp;doi=10.1186/s13098-019-0476-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF53">
<span class="label">53.</span><cite>Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Clegg LE, Penland RC, Bachina S, et al.  Cardiovasc Diabetol. 2019;18:138. doi: 10.1186/s12933-019-0942-x.</cite> [<a href="https://doi.org/10.1186/s12933-019-0942-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6805385/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31640705/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Effects%20of%20exenatide%20and%20open-label%20SGLT2%20inhibitor%20treatment,%20given%20in%20parallel%20or%20sequentially,%20on%20mortality%20and%20cardiovascular%20and%20renal%20outcomes%20in%20type%202%20diabetes:%20insights%20from%20the%20EXSCEL%20trial&amp;volume=18&amp;publication_year=2019&amp;pages=138&amp;pmid=31640705&amp;doi=10.1186/s12933-019-0942-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF54">
<span class="label">54.</span><cite>Liraglutide and cardiovascular outcomes in type 2 diabetes. Marso SP, Daniels GH, Brown-Frandsen K, et al.  N Engl J Med. 2016;375:311–322. doi: 10.1056/NEJMoa1603827.</cite> [<a href="https://doi.org/10.1056/NEJMoa1603827" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4985288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27295427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Liraglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes&amp;volume=375&amp;publication_year=2016&amp;pages=311-322&amp;pmid=27295427&amp;doi=10.1056/NEJMoa1603827&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF55">
<span class="label">55.</span><cite>Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. Marso SP, Bain SC, Consoli A, et al.  N Engl J Med. 2016;375:1834–1844. doi: 10.1056/NEJMoa1607141.</cite> [<a href="https://doi.org/10.1056/NEJMoa1607141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&amp;volume=375&amp;publication_year=2016&amp;pages=1834-1844&amp;pmid=27633186&amp;doi=10.1056/NEJMoa1607141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF56">
<span class="label">56.</span><cite>Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis. Krisanapan P, Sanpawithayakul K, Pattharanitima P, et al.  Diseases. 2024;12:14. doi: 10.3390/diseases12010014.</cite> [<a href="https://doi.org/10.3390/diseases12010014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10814593/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38248365/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diseases&amp;title=Safety%20and%20efficacy%20of%20GLP-1%20receptor%20agonists%20in%20type%202%20diabetes%20mellitus%20with%20advanced%20and%20end-stage%20kidney%20disease:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=12&amp;publication_year=2024&amp;pages=14&amp;pmid=38248365&amp;doi=10.3390/diseases12010014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF57">
<span class="label">57.</span><cite>Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Gong Y, Bai X, Zhang D, et al.  Lipids Health Dis. 2024;23:157. doi: 10.1186/s12944-024-02132-x.</cite> [<a href="https://doi.org/10.1186/s12944-024-02132-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11128128/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38796440/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lipids%20Health%20Dis&amp;title=Effect%20of%20DPP-4i%20inhibitors%20on%20renal%20function%20in%20patients%20with%20type%202%20diabetes%20mellitus:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20controlled%20trials&amp;volume=23&amp;publication_year=2024&amp;pages=157&amp;pmid=38796440&amp;doi=10.1186/s12944-024-02132-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF58">
<span class="label">58.</span><cite>Effects of DPP4 inhibitors on renal outcomes in diabetes mellitus: a systematic review and meta-analysis. Dalui SK, Chakraverty R, Yasmin N, Pattanaik S, Pandit K, Chatterjee S. Indian J Endocrinol Metab. 2021;25:283–292. doi: 10.4103/ijem.ijem_237_21.</cite> [<a href="https://doi.org/10.4103/ijem.ijem_237_21" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8793961/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35136733/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20J%20Endocrinol%20Metab&amp;title=Effects%20of%20DPP4%20inhibitors%20on%20renal%20outcomes%20in%20diabetes%20mellitus:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=25&amp;publication_year=2021&amp;pages=283-292&amp;pmid=35136733&amp;doi=10.4103/ijem.ijem_237_21&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF59">
<span class="label">59.</span><cite>Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. Green JB, Bethel MA, Armstrong PW, et al.  N Engl J Med. 2015;373:232–242. doi: 10.1056/NEJMoa1501352.</cite> [<a href="https://doi.org/10.1056/NEJMoa1501352" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26052984/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Effect%20of%20sitagliptin%20on%20cardiovascular%20outcomes%20in%20type%202%20diabetes&amp;volume=373&amp;publication_year=2015&amp;pages=232-242&amp;pmid=26052984&amp;doi=10.1056/NEJMoa1501352&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF60">
<span class="label">60.</span><cite>Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. Chen DY, Li YR, Mao CT, et al.  J Diabetes Investig. 2020;11:110–124. doi: 10.1111/jdi.13078.</cite> [<a href="https://doi.org/10.1111/jdi.13078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6944835/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31115964/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Investig&amp;title=Cardiovascular%20outcomes%20of%20vildagliptin%20in%20patients%20with%20type%C2%A02%20diabetes%20mellitus%20after%20acute%20coronary%20syndrome%20or%20acute%20ischemic%20stroke&amp;volume=11&amp;publication_year=2020&amp;pages=110-124&amp;pmid=31115964&amp;doi=10.1111/jdi.13078&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF61">
<span class="label">61.</span><cite>Dipeptidyl peptidase 4 inhibitors reduce the risk of adverse outcomes after acute kidney injury in diabetic patients. Liao HW, Cheng CY, Chen HY, Chen JY, Pan HC, Huang TM, Wu VC. Clin Kidney J. 2025;18:0. doi: 10.1093/ckj/sfae385.</cite> [<a href="https://doi.org/10.1093/ckj/sfae385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11806628/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39927258/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Kidney%20J&amp;title=Dipeptidyl%20peptidase%204%20inhibitors%20reduce%20the%20risk%20of%20adverse%20outcomes%20after%20acute%20kidney%20injury%20in%20diabetic%20patients&amp;volume=18&amp;publication_year=2025&amp;pages=0&amp;pmid=39927258&amp;doi=10.1093/ckj/sfae385&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF62">
<span class="label">62.</span><cite>Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. Wanner C, Cooper ME, Johansen OE, et al.  Clin Kidney J. 2021;14:226–236. doi: 10.1093/ckj/sfaa225.</cite> [<a href="https://doi.org/10.1093/ckj/sfaa225" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7857804/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33564423/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Kidney%20J&amp;title=Effect%20of%20linagliptin%20versus%20placebo%20on%20cardiovascular%20and%20kidney%20outcomes%20in%20nephrotic-range%20proteinuria%20and%20type%202%20diabetes:%20the%20CARMELINA%20randomized%20controlled%20trial&amp;volume=14&amp;publication_year=2021&amp;pages=226-236&amp;pmid=33564423&amp;doi=10.1093/ckj/sfaa225&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF63">
<span class="label">63.</span><cite>Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: a nationwide cohort study. Chen DY, Wang SH, Mao CT, et al.  Int J Cardiol. 2015;181:200–206. doi: 10.1016/j.ijcard.2014.12.029.</cite> [<a href="https://doi.org/10.1016/j.ijcard.2014.12.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25528312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cardiol&amp;title=Sitagliptin%20and%20cardiovascular%20outcomes%20in%20diabetic%20patients%20with%20chronic%20kidney%20disease%20and%20acute%20myocardial%20infarction:%20a%20nationwide%20cohort%20study&amp;volume=181&amp;publication_year=2015&amp;pages=200-206&amp;pmid=25528312&amp;doi=10.1016/j.ijcard.2014.12.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF64">
<span class="label">64.</span><cite>Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Bergmark BA, Bhatt DL, McGuire DK, et al.  Circulation. 2019;140:1004–1014. doi: 10.1161/CIRCULATIONAHA.119.040144.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.119.040144" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31362530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Metformin%20use%20and%20clinical%20outcomes%20among%20patients%20with%20diabetes%20mellitus%20with%20or%20without%20heart%20failure%20or%20kidney%20dysfunction:%20observations%20from%20the%20SAVOR-TIMI%2053%20trial&amp;volume=140&amp;publication_year=2019&amp;pages=1004-1014&amp;pmid=31362530&amp;doi=10.1161/CIRCULATIONAHA.119.040144&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF65">
<span class="label">65.</span><cite>Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study. Yi Y, Kwon EJ, Yun G, et al.  Sci Rep. 2024;14:2081. doi: 10.1038/s41598-024-52078-4.</cite> [<a href="https://doi.org/10.1038/s41598-024-52078-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10808543/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38267451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Impact%20of%20metformin%20on%20cardiovascular%20and%20kidney%20outcome%20based%20on%20kidney%20function%20status%20in%20type%202%20diabetic%20patients:%20a%20multicentric,%20retrospective%20cohort%20study&amp;volume=14&amp;publication_year=2024&amp;pages=2081&amp;pmid=38267451&amp;doi=10.1038/s41598-024-52078-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF66">
<span class="label">66.</span><cite>DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Nakamura K, Oe H, Kihara H, et al.  Cardiovasc Diabetol. 2014;13:110. doi: 10.1186/s12933-014-0110-2.</cite> [<a href="https://doi.org/10.1186/s12933-014-0110-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4149239/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25074318/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=DPP-4%20inhibitor%20and%20alpha-glucosidase%20inhibitor%20equally%20improve%20endothelial%20function%20in%20patients%20with%20type%202%20diabetes:%20EDGE%20study&amp;volume=13&amp;publication_year=2014&amp;pages=110&amp;pmid=25074318&amp;doi=10.1186/s12933-014-0110-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF67">
<span class="label">67.</span><cite>Insulin therapy is associated with an increased risk of carotid plaque in type 2 diabetes: a real-world study. Ke JF, Wang JW, Zhang ZH, Chen MY, Lu JX, Li LX. Front Cardiovasc Med. 2021;8:599545. doi: 10.3389/fcvm.2021.599545.</cite> [<a href="https://doi.org/10.3389/fcvm.2021.599545" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7882504/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33598483/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Cardiovasc%20Med&amp;title=Insulin%20therapy%20is%20associated%20with%20an%20increased%20risk%20of%20carotid%20plaque%20in%20type%202%20diabetes:%20a%20real-world%20study&amp;volume=8&amp;publication_year=2021&amp;pages=599545&amp;pmid=33598483&amp;doi=10.3389/fcvm.2021.599545&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF68">
<span class="label">68.</span><cite>Metformin use and risk of all-cause mortality and cardiovascular events in patients with chronic kidney disease-a systematic review and meta-analysis. Hu Y, Lei M, Ke G, Huang X, Peng X, Zhong L, Fu P. Front Endocrinol (Lausanne) 2020;11:559446. doi: 10.3389/fendo.2020.559446.</cite> [<a href="https://doi.org/10.3389/fendo.2020.559446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7575818/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33117278/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Endocrinol%20(Lausanne)&amp;title=Metformin%20use%20and%20risk%20of%20all-cause%20mortality%20and%20cardiovascular%20events%20in%20patients%20with%20chronic%20kidney%20disease-a%20systematic%20review%20and%20meta-analysis&amp;volume=11&amp;publication_year=2020&amp;pages=559446&amp;pmid=33117278&amp;doi=10.3389/fendo.2020.559446&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF69">
<span class="label">69.</span><cite>Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. JAMA. 2014;312:2668–2675. doi: 10.1001/jama.2014.15298.</cite> [<a href="https://doi.org/10.1001/jama.2014.15298" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4427053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25536258/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Metformin%20in%20patients%20with%20type%202%20diabetes%20and%20kidney%20disease:%20a%20systematic%20review&amp;volume=312&amp;publication_year=2014&amp;pages=2668-2675&amp;pmid=25536258&amp;doi=10.1001/jama.2014.15298&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF70">
<span class="label">70.</span><cite>Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis. Wang W, Zhou X, Kwong JS, Li L, Li Y, Sun X. Sci Rep. 2017;7:1717. doi: 10.1038/s41598-017-01965-0.</cite> [<a href="https://doi.org/10.1038/s41598-017-01965-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5431943/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28496176/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Efficacy%20and%20safety%20of%20thiazolidinediones%20in%20diabetes%20patients%20with%20renal%20impairment:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=7&amp;publication_year=2017&amp;pages=1717&amp;pmid=28496176&amp;doi=10.1038/s41598-017-01965-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF71">
<span class="label">71.</span><cite>Association of renal and cardiovascular safety with DPP-4 inhibitors vs. sulfonylureas in patients with type 2 diabetes and advanced chronic kidney disease. Yang CT, Lin WH, Li LJ, Ou HT, Kuo S. Clin Pharmacol Ther. 2021;110:464–472. doi: 10.1002/cpt.2262.</cite> [<a href="https://doi.org/10.1002/cpt.2262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33866549/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Association%20of%20renal%20and%20cardiovascular%20safety%20with%20DPP-4%20inhibitors%20vs.%20sulfonylureas%20in%20patients%20with%20type%202%20diabetes%20and%20advanced%20chronic%20kidney%20disease&amp;volume=110&amp;publication_year=2021&amp;pages=464-472&amp;pmid=33866549&amp;doi=10.1002/cpt.2262&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF72">
<span class="label">72.</span><cite>Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK. J Diabetes Complications. 2017;31:918–927. doi: 10.1016/j.jdiacomp.2017.01.011.</cite> [<a href="https://doi.org/10.1016/j.jdiacomp.2017.01.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28238556/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Complications&amp;title=Bile%20acid%20sequestrants%20for%20glycemic%20control%20in%20patients%20with%20type%202%20diabetes:%20a%20systematic%20review%20with%20meta-analysis%20of%20randomized%20controlled%20trials&amp;volume=31&amp;publication_year=2017&amp;pages=918-927&amp;pmid=28238556&amp;doi=10.1016/j.jdiacomp.2017.01.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF73">
<span class="label">73.</span><cite>Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Ray KK, Nicholls SJ, Li N, et al.  Lancet Diabetes Endocrinol. 2024;12:19–28. doi: 10.1016/S2213-8587(23)00316-9.</cite> [<a href="https://doi.org/10.1016/S2213-8587(23)00316-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38061370/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet%20Diabetes%20Endocrinol&amp;title=Efficacy%20and%20safety%20of%20bempedoic%20acid%20among%20patients%20with%20and%20without%20diabetes:%20prespecified%20analysis%20of%20the%20CLEAR%20Outcomes%20randomised%20trial&amp;volume=12&amp;publication_year=2024&amp;pages=19-28&amp;pmid=38061370&amp;doi=10.1016/S2213-8587(23)00316-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF74">
<span class="label">74.</span><cite>Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Rossi A, Masi D, Zilich R, et al.  Cardiovasc Diabetol. 2025;24:94. doi: 10.1186/s12933-025-02648-1.</cite> [<a href="https://doi.org/10.1186/s12933-025-02648-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11871825/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40022078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Lipid-lowering%20therapy%20and%20LDL%20target%20attainment%20in%20type%202%20diabetes:%20trends%20from%20the%20Italian%20Associations%20of%20Medical%20Diabetologists%20database&amp;volume=24&amp;publication_year=2025&amp;pages=94&amp;pmid=40022078&amp;doi=10.1186/s12933-025-02648-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF75">
<span class="label">75.</span><cite>Fibrate and the risk of cardiovascular disease among moderate chronic kidney disease patients with primary hypertriglyceridemia. Yen CL, Fan PC, Lee CC, et al.  Front Endocrinol (Lausanne) 2024;15:1333553. doi: 10.3389/fendo.2024.1333553.</cite> [<a href="https://doi.org/10.3389/fendo.2024.1333553" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10897040/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38414823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Endocrinol%20(Lausanne)&amp;title=Fibrate%20and%20the%20risk%20of%20cardiovascular%20disease%20among%20moderate%20chronic%20kidney%20disease%20patients%20with%20primary%20hypertriglyceridemia&amp;volume=15&amp;publication_year=2024&amp;pages=1333553&amp;pmid=38414823&amp;doi=10.3389/fendo.2024.1333553&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF76">
<span class="label">76.</span><cite>The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies. Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. J Clin Med. 2022;11:768. doi: 10.3390/jcm11030768.</cite> [<a href="https://doi.org/10.3390/jcm11030768" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8836930/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35160220/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=The%20effect%20of%20fibrates%20on%20kidney%20function%20and%20chronic%20kidney%20disease%20progression:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomised%20studies&amp;volume=11&amp;publication_year=2022&amp;pages=768&amp;pmid=35160220&amp;doi=10.3390/jcm11030768&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF77">
<span class="label">77.</span><cite>A systematic review on the safety and efficacy of PCSK9 inhibitors in lowering cardiovascular risks in patients with chronic kidney disease. Igweonu-Nwakile EO, Ali S, Paul S, et al.  Cureus. 2022;14:0. doi: 10.7759/cureus.29140.</cite> [<a href="https://doi.org/10.7759/cureus.29140" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9477547/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36128564/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cureus&amp;title=A%20systematic%20review%20on%20the%20safety%20and%20efficacy%20of%20PCSK9%20inhibitors%20in%20lowering%20cardiovascular%20risks%20in%20patients%20with%20chronic%20kidney%20disease&amp;volume=14&amp;publication_year=2022&amp;pages=0&amp;pmid=36128564&amp;doi=10.7759/cureus.29140&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF78">
<span class="label">78.</span><cite>Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. Koskinas KC, Siontis GC, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S. Eur Heart J. 2018;39:1172–1180. doi: 10.1093/eurheartj/ehx566.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehx566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29069377/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=Effect%20of%20statins%20and%20non-statin%20LDL-lowering%20medications%20on%20cardiovascular%20outcomes%20in%20secondary%20prevention:%20a%20meta-analysis%20of%20randomized%20trials&amp;volume=39&amp;publication_year=2018&amp;pages=1172-1180&amp;pmid=29069377&amp;doi=10.1093/eurheartj/ehx566&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF79">
<span class="label">79.</span><cite>Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Fischer LT, Hochfellner DA, Knoll L, Pöttler T, Mader JK, Aberer F. Cardiovasc Diabetol. 2021;20:89. doi: 10.1186/s12933-021-01283-w.</cite> [<a href="https://doi.org/10.1186/s12933-021-01283-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8070307/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33894772/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=Real-world%20data%20on%20metabolic%20effects%20of%20PCSK9%20inhibitors%20in%20a%20tertiary%20care%20center%20in%20patients%20with%20and%20without%20diabetes%20mellitus&amp;volume=20&amp;publication_year=2021&amp;pages=89&amp;pmid=33894772&amp;doi=10.1186/s12933-021-01283-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF80">
<span class="label">80.</span><cite>Inclisiran treatment for cardiovascular disease risk reduction: a systematic review and meta-analysis. Chen YF, Li S, Wang MJ, Wu MY, du ZC, Wei LP. J Coll Physicians Surg Pak. 2024;34:1090–1095. doi: 10.29271/jcpsp.2024.09.1090.</cite> [<a href="https://doi.org/10.29271/jcpsp.2024.09.1090" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39262011/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Coll%20Physicians%20Surg%20Pak&amp;title=Inclisiran%20treatment%20for%20cardiovascular%20disease%20risk%20reduction:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=34&amp;publication_year=2024&amp;pages=1090-1095&amp;pmid=39262011&amp;doi=10.29271/jcpsp.2024.09.1090&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF81">
<span class="label">81.</span><cite>Efficacy and safety of inclisiran a newly approved FDA drug: a systematic review and pooled analysis of available clinical studies. Cicero AF, Fogacci F, Zambon A, Toth PP, Borghi C. Am Heart J Plus. 2022;13:100127. doi: 10.1016/j.ahjo.2022.100127.</cite> [<a href="https://doi.org/10.1016/j.ahjo.2022.100127" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10978220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38560059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J%20Plus&amp;title=Efficacy%20and%20safety%20of%20inclisiran%20a%20newly%20approved%20FDA%20drug:%20a%20systematic%20review%20and%20pooled%20analysis%20of%20available%20clinical%20studies&amp;volume=13&amp;publication_year=2022&amp;pages=100127&amp;pmid=38560059&amp;doi=10.1016/j.ahjo.2022.100127&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF82">
<span class="label">82.</span><cite>Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Goto H, Iseri K, Hida N. Nephrol Dial Transplant. 2024;39:1016–1022. doi: 10.1093/ndt/gfad248.</cite> [<a href="https://doi.org/10.1093/ndt/gfad248" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11139516/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38012115/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nephrol%20Dial%20Transplant&amp;title=Fibrates%20and%20the%20risk%20of%20cardiovascular%20outcomes%20in%20chronic%20kidney%20disease%20patients&amp;volume=39&amp;publication_year=2024&amp;pages=1016-1022&amp;pmid=38012115&amp;doi=10.1093/ndt/gfad248&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF83">
<span class="label">83.</span><cite>Omega-3 fatty acid supplementation on lipid profiles in dialysis patients: meta-analysis. Chi H, Lin X, Huang H, Zheng X, Li T, Zou Y. Arch Med Res. 2014;45:469–477. doi: 10.1016/j.arcmed.2014.06.008.</cite> [<a href="https://doi.org/10.1016/j.arcmed.2014.06.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25010561/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch%20Med%20Res&amp;title=Omega-3%20fatty%20acid%20supplementation%20on%20lipid%20profiles%20in%20dialysis%20patients:%20meta-analysis&amp;volume=45&amp;publication_year=2014&amp;pages=469-477&amp;pmid=25010561&amp;doi=10.1016/j.arcmed.2014.06.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF84">
<span class="label">84.</span><cite>Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. Charytan DM, Sabatine MS, Pedersen TR, et al.  J Am Coll Cardiol. 2019;73:2961–2970. doi: 10.1016/j.jacc.2019.03.513.</cite> [<a href="https://doi.org/10.1016/j.jacc.2019.03.513" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31196453/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Efficacy%20and%20safety%20of%20evolocumab%20in%20chronic%20kidney%20disease%20in%20the%20FOURIER%20trial&amp;volume=73&amp;publication_year=2019&amp;pages=2961-2970&amp;pmid=31196453&amp;doi=10.1016/j.jacc.2019.03.513&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF85">
<span class="label">85.</span><cite>Effect of niacin on lipids and glucose in patients with type 2 diabetes: a meta-analysis of randomized, controlled clinical trials. Ding Y, Li Y, Wen A. Clin Nutr. 2015;34:838–844. doi: 10.1016/j.clnu.2014.09.019.</cite> [<a href="https://doi.org/10.1016/j.clnu.2014.09.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25306426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Nutr&amp;title=Effect%20of%20niacin%20on%20lipids%20and%20glucose%20in%20patients%20with%20type%202%20diabetes:%20a%20meta-analysis%20of%20randomized,%20controlled%20clinical%20trials&amp;volume=34&amp;publication_year=2015&amp;pages=838-844&amp;pmid=25306426&amp;doi=10.1016/j.clnu.2014.09.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF86">
<span class="label">86.</span><cite>Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Heart. 2016;102:198–203. doi: 10.1136/heartjnl-2015-308055.</cite> [<a href="https://doi.org/10.1136/heartjnl-2015-308055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4752613/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26370223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Heart&amp;title=Niacin%20therapy%20and%20the%20risk%20of%20new-onset%20diabetes:%20a%20meta-analysis%20of%20randomised%20controlled%20trials&amp;volume=102&amp;publication_year=2016&amp;pages=198-203&amp;pmid=26370223&amp;doi=10.1136/heartjnl-2015-308055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF87">
<span class="label">87.</span><cite>10. Cardiovascular disease and risk management: standards of care in diabetes-2025. American Diabetes Association Professional Practice Committee. Diabetes Care. 2025;48:0–38.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=10.%20Cardiovascular%20disease%20and%20risk%20management:%20standards%20of%20care%20in%20diabetes-2025&amp;volume=48&amp;publication_year=2025&amp;pages=0-38&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF88">
<span class="label">88.</span><cite>Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. Burnier M, Lin S, Ruilope L, Bader G, Durg S, Brunel P. Blood Press. 2019;28:358–374. doi: 10.1080/08037051.2019.1644155.</cite> [<a href="https://doi.org/10.1080/08037051.2019.1644155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31392910/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Blood%20Press&amp;title=Effect%20of%20angiotensin%20receptor%20blockers%20on%20blood%20pressure%20and%20renal%20function%20in%20patients%20with%20concomitant%20hypertension%20and%20chronic%20kidney%20disease:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=28&amp;publication_year=2019&amp;pages=358-374&amp;pmid=31392910&amp;doi=10.1080/08037051.2019.1644155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF89">
<span class="label">89.</span><cite>Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. Cheng J, Zhang W, Zhang X, et al.  JAMA Intern Med. 2014;174:773–785. doi: 10.1001/jamainternmed.2014.348.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2014.348" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24687000/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Effect%20of%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20all-cause%20mortality,%20cardiovascular%20deaths,%20and%20cardiovascular%20events%20in%20patients%20with%20diabetes%20mellitus:%20a%20meta-analysis&amp;volume=174&amp;publication_year=2014&amp;pages=773-785&amp;pmid=24687000&amp;doi=10.1001/jamainternmed.2014.348&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF90">
<span class="label">90.</span><cite>Comparative effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers for major renal outcomes in patients with diabetes: a 15-year cohort study. Wu HY, Peng CL, Chen PC, et al.  PLoS One. 2017;12:0. doi: 10.1371/journal.pone.0177654.</cite> [<a href="https://doi.org/10.1371/journal.pone.0177654" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5432180/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28505194/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Comparative%20effectiveness%20of%20angiotensin-converting%20enzyme%20inhibitors%20versus%20angiotensin%20II%20receptor%20blockers%20for%20major%20renal%20outcomes%20in%20patients%20with%20diabetes:%20a%2015-year%20cohort%20study&amp;volume=12&amp;publication_year=2017&amp;pages=0&amp;pmid=28505194&amp;doi=10.1371/journal.pone.0177654&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF91">
<span class="label">91.</span><cite>Effect of angiotensin receptor blocker and angiotensin converting enzyme inhibitor on kidney function and blood potassium level in Indonesian type 2 diabetes mellitus with hypertension: a three-month cohort study. Puspita FM, Yunir E, Agustina PS, Sauriasari R. Diabetes Metab Syndr Obes. 2021;14:3841–3849. doi: 10.2147/DMSO.S310091.</cite> [<a href="https://doi.org/10.2147/DMSO.S310091" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8434850/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34522111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab%20Syndr%20Obes&amp;title=Effect%20of%20angiotensin%20receptor%20blocker%20and%20angiotensin%20converting%20enzyme%20inhibitor%20on%20kidney%20function%20and%20blood%20potassium%20level%20in%20Indonesian%20type%202%20diabetes%20mellitus%20with%20hypertension:%20a%20three-month%20cohort%20study&amp;volume=14&amp;publication_year=2021&amp;pages=3841-3849&amp;pmid=34522111&amp;doi=10.2147/DMSO.S310091&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF92">
<span class="label">92.</span><cite>Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis. Pan G, Zhou X, Zhao J. Cardiovasc Ther. 2014;32:184–188. doi: 10.1111/1755-5922.12073.</cite> [<a href="https://doi.org/10.1111/1755-5922.12073" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24645740/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Ther&amp;title=Effect%20of%20telmisartan%20on%20atrial%20fibrillation%20recurrences%20in%20patients%20with%20hypertension:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=32&amp;publication_year=2014&amp;pages=184-188&amp;pmid=24645740&amp;doi=10.1111/1755-5922.12073&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF93">
<span class="label">93.</span><cite>RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Kumar V, Agarwal S, Saboo B, Makkar B. Int J Diabetes Dev Ctries. 2022;42:576–605. doi: 10.1007/s13410-022-01143-7.</cite> [<a href="https://doi.org/10.1007/s13410-022-01143-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9750845/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36536953/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Diabetes%20Dev%20Ctries&amp;title=RSSDI%20Guidelines%20for%20the%20management%20of%20hypertension%20in%20patients%20with%20diabetes%20mellitus&amp;volume=42&amp;publication_year=2022&amp;pages=576-605&amp;pmid=36536953&amp;doi=10.1007/s13410-022-01143-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF94">
<span class="label">94.</span><cite>A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan. Wu LS, Chang SH, Chang GJ, et al.  Cardiovasc Diabetol. 2016;15:56. doi: 10.1186/s12933-016-0365-x.</cite> [<a href="https://doi.org/10.1186/s12933-016-0365-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4818874/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27039185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=A%20comparison%20between%20angiotensin%20converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%20on%20end%20stage%20renal%20disease%20and%20major%20adverse%20cardiovascular%20events%20in%20diabetic%20patients:%20a%20population-based%20dynamic%20cohort%20study%20in%20Taiwan&amp;volume=15&amp;publication_year=2016&amp;pages=56&amp;pmid=27039185&amp;doi=10.1186/s12933-016-0365-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF95">
<span class="label">95.</span><cite>Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Wang K, Hu J, Luo T, et al.  Kidney Blood Press Res. 2018;43:768–779. doi: 10.1159/000489913.</cite> [<a href="https://doi.org/10.1159/000489913" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29794446/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Blood%20Press%20Res&amp;title=Effects%20of%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20II%20receptor%20blockers%20on%20all-cause%20mortality%20and%20renal%20outcomes%20in%20patients%20with%20diabetes%20and%20albuminuria:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=43&amp;publication_year=2018&amp;pages=768-779&amp;pmid=29794446&amp;doi=10.1159/000489913&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF96">
<span class="label">96.</span><cite>Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. Liu Y, Ma X, Zheng J, Jia J, Yan T. BMC Nephrol. 2017;18:206. doi: 10.1186/s12882-017-0605-7.</cite> [<a href="https://doi.org/10.1186/s12882-017-0605-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5493067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28666408/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Nephrol&amp;title=Effects%20of%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers%20on%20cardiovascular%20events%20and%20residual%20renal%20function%20in%20dialysis%20patients:%20a%20meta-analysis%20of%20randomised%20controlled%20trials&amp;volume=18&amp;publication_year=2017&amp;pages=206&amp;pmid=28666408&amp;doi=10.1186/s12882-017-0605-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF97">
<span class="label">97.</span><cite>Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease - propensity score matching analysis. Kim HJ, Lee MH, Jo SH, et al.  Circ J. 2019;84:83–90. doi: 10.1253/circj.CJ-19-0782.</cite> [<a href="https://doi.org/10.1253/circj.CJ-19-0782" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31776309/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circ%20J&amp;title=Effects%20of%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin-receptor%20blockers%20in%20heart%20failure%20with%20chronic%20kidney%20disease%20-%20propensity%20score%20matching%20analysis&amp;volume=84&amp;publication_year=2019&amp;pages=83-90&amp;pmid=31776309&amp;doi=10.1253/circj.CJ-19-0782&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF98">
<span class="label">98.</span><cite>Effect of mineralocorticoid receptor blockade on arterial stiffness and endothelial function: a meta-analysis of randomized trials. Sakima A, Arima H, Matayoshi T, Ishida A, Ohya Y. Hypertension. 2021;77:929–937. doi: 10.1161/HYPERTENSIONAHA.120.16397.</cite> [<a href="https://doi.org/10.1161/HYPERTENSIONAHA.120.16397" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33461316/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Hypertension&amp;title=Effect%20of%20mineralocorticoid%20receptor%20blockade%20on%20arterial%20stiffness%20and%20endothelial%20function:%20a%20meta-analysis%20of%20randomized%20trials&amp;volume=77&amp;publication_year=2021&amp;pages=929-937&amp;pmid=33461316&amp;doi=10.1161/HYPERTENSIONAHA.120.16397&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF99">
<span class="label">99.</span><cite>Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis. Takahashi S, Katada J, Daida H, Kitamura F, Yokoyama K. J Hum Hypertens. 2016;30:534–542. doi: 10.1038/jhh.2015.119.</cite> [<a href="https://doi.org/10.1038/jhh.2015.119" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4981731/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26674759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Hum%20Hypertens&amp;title=Effects%20of%20mineralocorticoid%20receptor%20antagonists%20in%20patients%20with%20hypertension%20and%20diabetes%20mellitus:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=30&amp;publication_year=2016&amp;pages=534-542&amp;pmid=26674759&amp;doi=10.1038/jhh.2015.119&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF100">
<span class="label">100.</span><cite>Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: a systematic review and meta-analysis. Chen Q, Liang Y, Yan J, Du Y, Li M, Chen Z, Zhou J. Diabetes Res Clin Pract. 2023;195:110210. doi: 10.1016/j.diabres.2022.110210.</cite> [<a href="https://doi.org/10.1016/j.diabres.2022.110210" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36509181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Res%20Clin%20Pract&amp;title=Efficacy%20and%20safety%20of%20non-steroidal%20mineralocorticoid%20receptor%20antagonists%20for%20renal%20outcomes:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=195&amp;publication_year=2023&amp;pages=110210&amp;pmid=36509181&amp;doi=10.1016/j.diabres.2022.110210&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF101">
<span class="label">101.</span><cite>Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis. Gu X, Jiang S, Yang Y, Li W. Diabetol Metab Syndr. 2024;16:14. doi: 10.1186/s13098-023-01251-2.</cite> [<a href="https://doi.org/10.1186/s13098-023-01251-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10782753/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38212831/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetol%20Metab%20Syndr&amp;title=Effects%20of%20finerenone%20and%20glucagon-like%20peptide%201%20receptor%20agonists%20on%20cardiovascular%20and%20renal%20outcomes%20in%20type%202%20diabetes%20mellitus:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=16&amp;publication_year=2024&amp;pages=14&amp;pmid=38212831&amp;doi=10.1186/s13098-023-01251-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF102">
<span class="label">102.</span><cite>Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes. Filippatos G, Anker SD, Agarwal R, et al.  Circulation. 2021;143:540–552. doi: 10.1161/CIRCULATIONAHA.120.051898.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.120.051898" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7864612/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33198491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Finerenone%20and%20cardiovascular%20outcomes%20in%20patients%20with%20chronic%20kidney%20disease%20and%20type%202%20diabetes&amp;volume=143&amp;publication_year=2021&amp;pages=540-552&amp;pmid=33198491&amp;doi=10.1161/CIRCULATIONAHA.120.051898&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF103">
<span class="label">103.</span><cite>Finerenone in patients with chronic kidney disease and type 2 diabetes according to baseline HbA1c and insulin use: an analysis from the FIDELIO-DKD study. Rossing P, Burgess E, Agarwal R, et al.  Diabetes Care. 2022;45:888–897. doi: 10.2337/dc21-1944.</cite> [<a href="https://doi.org/10.2337/dc21-1944" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9271031/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35061867/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Finerenone%20in%20patients%20with%20chronic%20kidney%20disease%20and%20type%202%20diabetes%20according%20to%20baseline%20HbA1c%20and%20insulin%20use:%20an%20analysis%20from%20the%20FIDELIO-DKD%20study&amp;volume=45&amp;publication_year=2022&amp;pages=888-897&amp;pmid=35061867&amp;doi=10.2337/dc21-1944&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF104">
<span class="label">104.</span><cite>2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Heidenreich PA, Bozkurt B, Aguilar D, et al.  Circulation. 2022;145:0–1032. doi: 10.1161/CIR.0000000000001063.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000001063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35363499/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=2022%20AHA/ACC/HFSA%20guideline%20for%20the%20management%20of%20heart%20failure:%20a%20report%20of%20the%20American%20College%20of%20Cardiology/American%20Heart%20Association%20Joint%20Committee%20on%20clinical%20practice%20guidelines&amp;volume=145&amp;publication_year=2022&amp;pages=0-1032&amp;pmid=35363499&amp;doi=10.1161/CIR.0000000000001063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF105">
<span class="label">105.</span><cite>2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Marx N, Federici M, Schütt K, et al.  Eur Heart J. 2023;44:4043–4140. doi: 10.1093/eurheartj/ehad881.</cite> [<a href="https://doi.org/10.1093/eurheartj/ehad881" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38195096/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=2023%20ESC%20guidelines%20for%20the%20management%20of%20cardiovascular%20disease%20in%20patients%20with%20diabetes&amp;volume=44&amp;publication_year=2023&amp;pages=4043-4140&amp;pmid=38195096&amp;doi=10.1093/eurheartj/ehad881&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF106">
<span class="label">106.</span><cite>Effects of the nonsteroidal MRA finerenone with and without concomitant SGLT2 inhibitor use in heart failure. Vaduganathan M, Claggett BL, Kulac IJ, et al.  Circulation. 2025;151:149–158. doi: 10.1161/CIRCULATIONAHA.124.072055.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.124.072055" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11732259/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39340828/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Effects%20of%20the%20nonsteroidal%20MRA%20finerenone%20with%20and%20without%20concomitant%20SGLT2%20inhibitor%20use%20in%20heart%20failure&amp;volume=151&amp;publication_year=2025&amp;pages=149-158&amp;pmid=39340828&amp;doi=10.1161/CIRCULATIONAHA.124.072055&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF107">
<span class="label">107.</span><cite>Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. Cooper LB, Lippmann SJ, Greiner MA, et al.  J Am Heart Assoc. 2017;6:0. doi: 10.1161/JAHA.117.006540.</cite> [<a href="https://doi.org/10.1161/JAHA.117.006540" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5779000/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29275368/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Heart%20Assoc&amp;title=Use%20of%20mineralocorticoid%20receptor%20antagonists%20in%20patients%20with%20heart%20failure%20and%20comorbid%20diabetes%20mellitus%20or%20chronic%20kidney%20disease&amp;volume=6&amp;publication_year=2017&amp;pages=0&amp;pmid=29275368&amp;doi=10.1161/JAHA.117.006540&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF108">
<span class="label">108.</span><cite>Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial. Agarwal R, Joseph A, Anker SD, et al.  J Am Soc Nephrol. 2022;33:225–237. doi: 10.1681/ASN.2021070942.</cite> [<a href="https://doi.org/10.1681/ASN.2021070942" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8763180/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34732509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Soc%20Nephrol&amp;title=Hyperkalemia%20risk%20with%20finerenone:%20results%20from%20the%20FIDELIO-DKD%20trial&amp;volume=33&amp;publication_year=2022&amp;pages=225-237&amp;pmid=34732509&amp;doi=10.1681/ASN.2021070942&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF109">
<span class="label">109.</span><cite>Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems. Baryakova TH, Pogostin BH, Langer R, McHugh KJ. Nat Rev Drug Discov. 2023;22:387–409. doi: 10.1038/s41573-023-00670-0.</cite> [<a href="https://doi.org/10.1038/s41573-023-00670-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10041531/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36973491/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Drug%20Discov&amp;title=Overcoming%20barriers%20to%20patient%20adherence:%20the%20case%20for%20developing%20innovative%20drug%20delivery%20systems&amp;volume=22&amp;publication_year=2023&amp;pages=387-409&amp;pmid=36973491&amp;doi=10.1038/s41573-023-00670-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF110">
<span class="label">110.</span><cite>Improving medication adherence in cardiometabolic disease: practical and regulatory implications. Ferdinand KC, Senatore FF, Clayton-Jeter H, et al.  J Am Coll Cardiol. 2017;69:437–451. doi: 10.1016/j.jacc.2016.11.034.</cite> [<a href="https://doi.org/10.1016/j.jacc.2016.11.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5604316/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28126162/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Coll%20Cardiol&amp;title=Improving%20medication%20adherence%20in%20cardiometabolic%20disease:%20practical%20and%20regulatory%20implications&amp;volume=69&amp;publication_year=2017&amp;pages=437-451&amp;pmid=28126162&amp;doi=10.1016/j.jacc.2016.11.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF111">
<span class="label">111.</span><cite>Effectiveness of single-tablet combination therapy in improving adherence and persistence and the relation to clinical and economic outcomes. Paoli C, Linder J, Gurjar K, Thakur D, Wyckmans J, Grieve S. J Health Econ Outcomes Res. 2024;11:8–22. doi: 10.36469/001c.91396.</cite> [<a href="https://doi.org/10.36469/001c.91396" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10948140/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38500521/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Health%20Econ%20Outcomes%20Res&amp;title=Effectiveness%20of%20single-tablet%20combination%20therapy%20in%20improving%20adherence%20and%20persistence%20and%20the%20relation%20to%20clinical%20and%20economic%20outcomes&amp;volume=11&amp;publication_year=2024&amp;pages=8-22&amp;pmid=38500521&amp;doi=10.36469/001c.91396&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF112">
<span class="label">112.</span><cite>Patient-reported outcomes and treatment adherence in type 2 diabetes using natural language processing: wave 8 of the Observational International Diabetes Management Practices Study. Chan JC, Mbanya JC, Chantelot JM, et al.  J Diabetes Investig. 2024;15:1306–1316. doi: 10.1111/jdi.14228.</cite> [<a href="https://doi.org/10.1111/jdi.14228" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11363103/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38840439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Investig&amp;title=Patient-reported%20outcomes%20and%20treatment%20adherence%20in%20type%E2%80%892%20diabetes%20using%20natural%20language%20processing:%20wave%208%20of%20the%20Observational%20International%20Diabetes%20Management%20Practices%20Study&amp;volume=15&amp;publication_year=2024&amp;pages=1306-1316&amp;pmid=38840439&amp;doi=10.1111/jdi.14228&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF113">
<span class="label">113.</span><cite>Management protocols of stable coronary artery disease in India: executive summary. Mishra S, Ray S, Dalal JJ, et al.  Indian Heart J. 2016;68:868–873. doi: 10.1016/j.ihj.2016.11.318.</cite> [<a href="https://doi.org/10.1016/j.ihj.2016.11.318" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5143826/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27931562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20Heart%20J&amp;title=Management%20protocols%20of%20stable%20coronary%20artery%20disease%20in%20India:%20executive%20summary&amp;volume=68&amp;publication_year=2016&amp;pages=868-873&amp;pmid=27931562&amp;doi=10.1016/j.ihj.2016.11.318&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF114">
<span class="label">114.</span><cite>11. Chronic kidney disease and risk management: standards of care in diabetes-2025. American Diabetes Association Professional Practice Committee. Diabetes Care. 2025;48:0–51.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=11.%20Chronic%20kidney%20disease%20and%20risk%20management:%20standards%20of%20care%20in%20diabetes-2025&amp;volume=48&amp;publication_year=2025&amp;pages=0-51&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF115">
<span class="label">115.</span><cite>2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Arnett DK, Blumenthal RS, Albert MA, et al.  Circulation. 2019;140:0–646. doi: 10.1161/CIR.0000000000000678.</cite> [<a href="https://doi.org/10.1161/CIR.0000000000000678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7734661/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30879355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=2019%20ACC/AHA%20guideline%20on%20the%20primary%20prevention%20of%20cardiovascular%20disease:%20a%20report%20of%20the%20American%20College%20of%20Cardiology/American%20Heart%20Association%20Task%20Force%20on%20clinical%20practice%20guidelines&amp;volume=140&amp;publication_year=2019&amp;pages=0-646&amp;pmid=30879355&amp;doi=10.1161/CIR.0000000000000678&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="REF116">
<span class="label">116.</span><cite>InSH consensus guideline for the management of hypertension, 2023. Gupta R, Maheshwari A, Verma N, Narasingan SN, Tripathi K, Joshi S, Manoria PC. Hypertens J. 2023;9:57–132.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Hypertens%20J&amp;title=InSH%20consensus%20guideline%20for%20the%20management%20of%20hypertension,%202023&amp;volume=9&amp;publication_year=2023&amp;pages=57-132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Cureus are provided here courtesy of <strong>Cureus Inc.</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.7759/cureus.88561"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/cureus-0017-00000088561.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (658.7 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12371295/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12371295/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12371295%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12371295/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12371295/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12371295/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12371295/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12371295/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12371295/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="6RUMBmWYKPzPshLzqmRT9Bep3D9Oi0pIGjO4TEZ1cpEeQ2zQwk0DoYWwod7gd9ai">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
